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Obesity is associated with numerous co-morbidities, such as chronic low-grade 
inflammation, oxidative stress, insulin resistance, cardiovascular disease, and some 
cancers. However, the role of estrogen in the susceptibility to obesity and its co-
morbidities is not clear.  To determine the role of estrogen in the above morbidities, we 
used C57BL/6J mice (15/group): 1)males 2)nonovariectomized females (novx) 
3)ovariectomized females (ovx) and 4) ovariectomized females supplemented with 
estrogen (ovx-E), which were randomized to receive a 30% calorie-restricted, low-fat or 
high-fat diet. Our results showed that male and ovx-female mice were more susceptible to 
obesity compared to novx-female and ovx-female+E mice. Specifically, we observed that 
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estrogen protected novx-female and ovx-female+E mice from adiposity and glucose 
intolerance by decreasing adipocyte size and key adipogenic and lipogenic mRNA 
expression levels. Further experimentation established that estrogen decreased abdominal 
adiposity by decreasing the number of large adipocytes. Our findings implied that 
estrogen stimulated lipolysis in novx-female and ovx-female+E mice. Additionally, the 
enlarged adipocytes observed in the male and ovx-female mice were accompanied with 
crown-like structures surrounding necrotic adipocytes and F480+ macrophages and 
elevated mRNA expression levels of CD68, IL6, and TNFα. Lastly, male and ovx-female 
mice exhibited liver steatosis, elevated serum ALT levels, and increased insulin 
resistance. To determine if there were sex differences in oxidative stress, we showed that 
estrogen protected the novx-female and ovx-female+E mice from adipose tissue oxidative 
stress as evidenced by fewer γH2AX stained nuclei and lower iNOS, P47x, GP90x, but 
higher catalase mRNA levels. In order to further understand the role of estrogen in 
adipocyte inflammation, we differentiated 3t3L1 pre-adipocytes in charcoal-stripped FBS 
+/- 1nM estrogen. Our findings mimicked our in vivo results; the presence of estrogen 
significantly decreased adipogenesis and down regulated IL6, TNFα, and GP90x in 3t3L1 
adipocytes. Additionally, using 4-hydroxytamoxifen, we demonstrated that the protective 
effects of estrogen on IL6 and TNFα mRNA expression were blocked; suggesting that 
estrogen could mediate its anti-inflammatory effects through ERα. In conclusion, this 
dissertation demonstrates that estrogen protects female mice from obesity-associated 
inflammation, oxidative stress, and insulin resistance by altering adipocyte morphology 
possibly through ERα.  
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Chapter 1: Introduction 
 
1.1 Obesity Background 
 According to the World Health Organization (WHO), obesity is a disease 
that is characterized by the accumulation of excess weight in the form of adipose tissue 
and is formally defined as having a body mass index (BMI) of >30kg/m
2 
[1]. An 
individual can become obese for various reasons; however, most often, obesity is caused 
by a positive energy balance. Energy balance is achieved when energy intake equals 
energy expenditure. In regards to obesity, energy intake refers to food consumption and 
energy “out” includes components of energy expenditure such as physical activity, 
metabolic rate, and thermogenesis. When energy intake exceeds energy output, you 
achieve a positive energy balance and over time this can lead to obesity. In the past 
twenty years, Americans have consumed more food daily than ever before. According to 
the USDA, Americans are consuming 500 calories more per day compared to the average 
caloric intake in 1970 [2]. Moreover, Americans are less active compared to previous 
generations and this is partly due to the increase in “desk” jobs. Research has shown that 
less than 5% American adults meet the recommended daily physical activity 
requirements [3]. Physical activity can account for 15-30% of daily energy expenditure 
and metabolic rate can account for as much as 60-75% of energy expenditure. Moreover, 
metabolic rate, which is largely dependent on lean body mass, is measured during a 
resting state, when an individual is not exercising [4]. Typically, metabolic rate is 
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measured after 8-12 hrs of fasting [5]. Thermogenesis or diet-induced thermogenesis can 
account for 5-10% of an individual’s energy expenditure. In summary, obesity is a result 
of energy imbalance and currently this disease is affecting more than one-third of 
Americans and is expected to increase [6].  
As mentioned previously, obesity is the state of excess accumulation of adipose 
tissue. Adipose tissue can increase by stimulating lipoprotein lipase activity and 
increasing adipocyte size (adipocyte hypertrophy) [7]. Or, it can increase by creating 
adipocytes de novo thru adipogenesis (adipocyte hyperplasia) [8]. Adipose tissue can be 
stored in the subcutaneous depots or visceral abdominal depots. Both depots have unique 
characteristics, but visceral adipose tissue is also known as the metabolically active 
adipose tissue and has been highly correlated with morbidities such as diabetes and 
cardiovascular disease, which are also associated with obesity [9, 10]. More importantly 
there are distinct sex differences in obesity specifically in adipose tissue deposition.  
 
1.2 Sex Differences in Obesity 
1.2.1 Evidence from Epidemiology Studies 
 Globally, obesity is becoming a serious epidemic. Again, obesity is characterized 
by having a BMI of greater than or equal to 30kg/m
2
.  More recently, obesity has been 
further characterized based on adipose tissue distribution. Adipose tissue can be stored in 
the subcutaneous or intra-abdominal regions. In general, females have a higher 
percentage of adipose tissue compared to males; however, there are clear differences in 
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the way males and females deposit the excess adipose tissue. Pre-menopausal females 
tend to store the excess adipose tissue subcutaneously, in contrast, males deposit the 
excess adipose tissue in the abdominal region [11].  
 Subcutaneous and abdominal fat have different biological and metabolic effects 
on the physiology of the body. For example, excess abdominal adipose tissue has been 
linked to various harmful morbidities associated with obesity, such has chronic low-grade 
inflammation, oxidative stress, and insulin resistance, [12]. Moreover, abdominal 
adiposity has been found to be a strong predictor of insulin resistance among men and 
women over 50 years of age [13]. There are two main hypotheses to explain the 
relationship between abdominal adiposity and these co-morbidities. The first hypothesis 
suggests that abdominal adipose tissue is responsible for the excessive pro-inflammatory 
adipokines that are released thus contributing to chronic low-grade inflammation [14]. 
The second hypothesis proposes that the high amount of free fatty acids released from 
excess abdominal tissue in the obese state passes through the portal vein leading to a 
higher probability of developing liver steatosis, which can increased the risk of insulin 
resistance  [11]. Therefore, these hypotheses provide insight into why the accumulation 
of abdominal adiposity causes harmful metabolic consequences in an obese state.   
 In addition to the metabolic differences noted above, there are sex differences in 
abdominal adipose tissue metabolism. For example, studies have shown that the fatty acid 
turnover in visceral fat is higher in males compared to females [15-17]. Specifically, the 
lipolytic and lipogenic activity in males’ adipocytes is much higher compared to females 
4 
 
[15]. This difference may be due to differences in estrogen signaling between males and 
pre-menopausal women [16, 17]. The various receptors for estrogen (ER) can be found in 
adipose tissue. ERα is present in pre-adipocytes and ERα and ERβ are present in mature 
adipocytes [18].  Some studies suggest that the ratio of ERα/ERβ may differ between 
sexes; however, the evidence is still questionable and warrants further investigation.  It is 
well established that estrogen in the pre-menopausal phase protects females against the 
accumulation of abdominal adipose tissue; however, this protection is lost during the 
menopause transition.  The mechanism by which estrogen mediates this protection has is 
not fully understood. 
 The pattern of excess adipose tissue accumulated in post-menopausal women is 
similar to that seen in men. For instance, epidemiological studies show that as women age 
the tendency to accumulate adipose tissue in the abdominal region increases [19, 20].  A 
possible explanation for the difference in adipose tissue accumulation between pre and 
post-menopausal phases may be in the differences of the enzymatic activity of the 
enzymes regulating lipolysis and lipogenesis.  Lipoprotein lipase (LPL) is a key enzyme 
that transports lipids (e.g., free fatty acids) across the membranes of adipocytes in order 
to be stored in the form of lipid droplets. Investigators show that the lipoprotein lipase 
(LPL) activity is higher in the gluteal-femoral adipose tissue depots of pre-menopausal 
women compared to the abdominal region of post-menopausal women [21].  Thus, 
suggesting that pre-menopausal females deposit adipose tissue in the femoral region over 
the abdominal reigon and this preference could be lost with a decline in estrogen levels 
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[21]. Longitudinal studies have provided essential data to confirm the above findings. By 
controlling for age and total fat mass, post-menopausal females had significantly more 
intra-abdominal adipose tissue compared to pre-menopausal females; therefore, implying 
the importance of estrogen in adipose tissue deposition [22]. Moreover, several cross-
sectional and longitudinal studies using a retrospective approach, have investigated the 
effects of hormone-replacement therapy (HRT) and body fat distribution.  Results from 
these studies show that post-menopausal women treated with HRT had a lower waist to 
hip ratio and the activity of LPL in abdominal fat  was significantly decreased [23, 24].   
Thus, epidemiological data suggests that estrogen protects women from accumulating 
excess adipose tissue in the abdominal region.  
 Although epidemiological studies are very useful for establishing relationships 
and associations, they offer limited understanding into the mechanism of the observed 
sex differences in adiposity. Therefore, in order to gain a more thorough understanding of 
the sex differences in obesity, experimental models have been utilized; specifically, diet-
induced and transgenic obese mouse models and cell culture models.  
1.2.2 Experimental Studies 
 Animal studies conducted to understand sex differences in obesity have included 
both in vivo and in vitro models. Researchers have used diet-induced obesity and 
transgenic mouse models and also 3t3L1 mouse adipocytes to identify the potential 
mechanisms that may explain the sex differences in adiposity.  
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 The majority of diet-induced obesity animal studies provide a high-fat diet (e.g., 
45-60% kcals from fat) to the animals, usually, for a minimum of 10 weeks. Our lab 
established that when exposed to a high-fat diet, male mice had a greater propensity of 
gaining body weight than female mice. However, ovariectomy eliminated the protection 
of female mice to gaining weight; in fact, ovariectomized female mice (ovx-female) 
mimicked male mice in their susceptibility to weight gain [25]. In order to determine 
whether the protective effects of estrogen against adiposity were due to alterations in 
food intake or energy expenditure, Rogers et al conducted a mouse study that included 
both ovx-female mice and sham-ovx-female mice. Briefly, results indicated no changes 
in food intake between the groups, but they did observe a significant decrease in both 
metabolic rate and ambulatory activity in the ovx-female mice, thus suggesting estrogen 
may protect female mice from obesity by increasing metabolic rate and ambulatory 
activity [26].  Estrogen may increase metabolic rate by increasing fat oxidation. D’eon et 
al. used pair-fed ovx-female mice supplemented with a placebo or estrogen and showed 
that estrogen treatment increased the expression of genes associated with lipid oxidation 
in the skeletal muscle of female mice [27].  Other researchers have shown that site-
specific reductions of estrogen receptor-alpha (ERα) in the ventromedial nucleus of the 
hypothalamus results in a decrease in voluntary ambulatory activity but no change in 
food intake; therefore, providing evidence that estrogen may protect against obesity by 
affecting physical activity, possibly via ERα [28].  To further understand the role of 
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estrogen and ERα in the sex differences in obesity, researchers have utilized transgenic 
mouse models as well.  
 Two mouse models that have been utilized to study the role of estrogen in 
susceptibility to obesity are estrogen receptor-alpha knockout (ERαKO) and aromatase 
knockout mice (ArKO).  ERαKO mice lack functional ERα, thus they are not able to 
mediate the actions of estrogen; both ERαKO male and female mice are sterile.   Studies 
have shown that ERαKO mice have a higher propensity of becoming obese compared to 
wild-type mice. In fact, male and female ERαKO mice have 50-100% more adipose 
tissue due to an increase in adipocyte size and number compared to wild-type control 
mice [29-31].  Even though ERβ is also expressed in adipose tissue, studies show that 
knocking out ERβ does not affect the susceptibility to obesity [29-31]. Therefore, the 
above studies suggest that ERα rather than ERβ may be key gene in understanding the sex 
differences in adiposity. Furthermore, ERα may play an essential role in modulating body 
weight by altering energy expenditure.  
 Research has implied that the increase in adipose tissue observed in the ERαKO 
mice could be due to alterations in energy expenditure. Heine et al. confirmed that there 
were no differences in food intake in the ERαKO mice compared to the wild-type mice. 
However, his studies discovered that energy expenditure was decreased in the ERαKO 
mice relative to the wild-type mice [32]. Furthermore, it has been establish that estrogen 
replacement in wild-type ovariectomized female mice (ovx-female) can reverse obesity. 
However, in ERαKO ovx-female mice, estrogen supplementation was not able to reverse 
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the effects of ovariectomy; thus, the above findings suggest that estrogen may act via 
ERα to protect against obesity, possibly by increasing physical activity and metabolic rate 
[33].  
 Another transgenic mouse model that has been used to better understand the 
protective role of estrogen against obesity is the ArKO mouse. ArKO mice lack a 
functional Cyp19 gene, which encodes aromatase.   Aromatase is a cytochrome P-450 
enzyme
 
that catalyzes the rate-limiting step in the synthesis of estrogen from androgen 
[34].  Aromatase is found in estrogen-producing cells such as the adrenal glands and 
white adipose tissue [35].  Because ArKO mice lack a functional Cyp19 gene, their 
tissues cannot synthesize endogenous estrogen and consequently have lower circulating 
levels of estrogen. Using both male and female ArKO mice, Jones et al. observed a 
significant increase in intra-abdominal adipose tissue compared to wild-type mice [36]. 
Moreover, this increase in adiposity was due to a decrease in voluntary ambulatory 
activity and not hyperphagia (increased food intake) [36]. Others have suggested that the 
increase in intra-abdominal adiposity observed in these mice is due to an increase in 
adipocyte volume as evidenced by increased mRNA expression levels of leptin and 
lipoprotein lipase [37]. However, enlarged adipocytes can be reduced when ArKO female 
mice are supplemented with estrogen [37]. Overall, evidence shows that the estrogen 
signaling pathway plays an essential role in the modulation of body adiposity.  To 
determine if estrogen has a direct effect on adipocyte biology, researchers have employed 
cell culture models in order to determine how estrogen affects the biology of fat cells, 
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such as the adipogenesis assay with 3t3L1 pre-adipocytes [38, 39]. For example, Homma 
et al. found that estrogen decreased lipoprotein lipase (LPL) mRNA as well as 
triglyceride accumulation in genetically manipulated 3T3-L1 adipocytes stably 
expressing ERα [38]. Moreover, Okazaki et al. determined that the presence of estrogen 
inhibit adipogenesis in 3t3L1 adipocytes that expressed both ERα and ERβ [39]. 
Although the above studies provide insight into the role of estrogen in adipocyte 
morphology they are limited in their findings and the relationship between estrogen and 
adipogenesis should be further understood.  
1.2.3 The role of Estrogen in Adipocyte Morphology 
An individual can gain adipose tissue by increasing adipocyte size (hypertrophy) 
or adipocyte number (hyperplasia) [7, 8]. Adipocyte size is regulated by a balance 
between lipogenesis and lipolysis, which are both influenced by hormones [40]. 
Adipocyte number is regulated by adipogenesis, which is defined as the formation of 
adipocytes from pre-adipocytes. Adipogenesis is a tightly regulated process that is 
strongly influenced by hormones such as leptin and insulin [41, 42]. The role of estrogen 
in understanding adipocyte morphology is not thoroughly understood.  
.  Lipogenesis is the process of increasing adipocyte size by increasing the 
deposition of triglycerides into lipid droplets.  This process is facilitated by the enzyme 
lipoprotein lipase (LPL). The enzymatic activity of LPL can be modulated by hormones 
such has insulin [43].  On the other hand, lipolysis is the process of decreasing adipocyte 
size by activating lipases. Hormone sensitive lipase (HSL) is an enzyme that degrades 
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triglycerides into free fatty acids and glycerol [44]. Hormones such as epinephrine, 
norepinephrine, glucagon and cortisol can activate HSL via G protein-coupled receptors.  
Activation of these receptors stimulates adenylate cyclase, which increases the 
production of cyclic-AMP production, which triggers protein kinase A (PKA) via 
phosphorylation (P-PKA). P-PKA can fuel the breakdown of the lipid droplet in the 
adipocyte by activating HSL and other lipases such as adipose triglyceride lipase 
(ATGL). ATGL is believed to cleave the first free fatty acid (FFA) from the 
triacylglyceride creating a diacylglyceride. HSL further degrades the diacylglyceride into 
a monoacylglyceride and a FFA. 
Adipocyte number is tightly regulated by adipogenesis. Adipocytes are derived 
from multipotent mesenchymal stem cells that have committed to the adipocyte lineage 
[45]. The process of a pre-adipocyte becoming an adipocyte requires that the cell acquire 
the machinery necessary for lipid transport, synthesis, and storage. In order for this 
transformation to take place, the expression of key genes and the activation of essential 
transcription factors are necessary [46]. Key transcription factors necessary for 
adipogenesis include the nuclear receptor peroxisome proliferator receptor-gamma 
(PPARγ) and members of the CCAAT-enhancer binding proteins (C/EBPs) [47]. 
However, recent research has indicated the importance of other genes such has lipin1, 
which have been established as a key gene for adipocyte development as evidenced by 
the fld lipin1 deficient mouse studies [48].  
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There is conclusive evidence supporting the notion that estrogen modulates the 
lipogenesis/lipolysis balance [29, 37]. Estrogen may affect lipogenesis by affecting the 
amount of LPL.  Studies show that estrogen suppresses lipoprotein lipase (LPL) 
transcription possibly due to an estrogen response element that is located in the promoter 
region of this gene [38].  Furthermore, using pair-fed ovx-female mice supplemented 
with a placebo or estrogen pellet, D’eon et al. showed that estrogen supplementation 
decreased adipocyte size through the regulation of perilipin [27]. Perilipin is a protein 
that coats lipid droplets in adipocytes; it is a gene that plays an essential role in the 
packaging of lipids in the fat cells. Moreover, perilipin also protects the lipid droplets 
from being degraded by the lipases HSL and ATGL [49]. Even though evidence suggests 
that estrogen modulates the activity of most lipases involved in lipolysis, the exact 
mechanism by which estrogen affects their activity is not clear [18, 39]. In regards to the 
regulation of adipocyte number by estrogen, most studies show that estrogen inhibits 
adipocyte differentiation; however, the mechanism behind this inhibition is unknown.  
In summary, the role of estrogen in adipocyte size and number is still not 
understood. Specifically, the mechanisms by which estrogen alters lipolysis and 
adipogenesis still need to be understood. Overall, there are sex differences in corpulence 
and thus adiposity. These disparities can affect the susceptibility to the co-morbidities of 
obesity, such as inflammation, oxidative stress and insulin resistance.  
 
1.3 Sex Differences in Obesity-associated Inflammation and Oxidative stress 
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1.3.2 Evidence from Epidemiology Studies 
 Obesity has been shown to be positively correlated with inflammation and 
oxidative stress [8, 50]. Specifically, excess visceral adipose tissue is associated with a 
low-grade chronic inflammatory state and has been shown to over-express pro-
inflammatory factors such as interleukin-6 (IL6) and tumor necrosis factor-alpha (TNFα), 
possibly due to the high level of macrophages recruited to the adipose tissue [51-53]. As 
previously mentioned males and post-menopausal females primarily deposit adipose 
tissue in the abdominal region and thus can be more susceptible to the above co-
morbidities [19, 23]. Moreover, the expression of factors associated with inflammation 
and oxidative can potentially modulate markers of insulin resistance [54, 55]. Therefore, 
in addition to sex differences in adiposity, there are also sex differences in markers of 
inflammation and oxidative stress.  
 Cartier et al. showed that after adjusting for visceral adiposity, pre-menopausal 
females had significantly lower serum TNFα levels than males [56]. Furthermore, other 
studies have shown that pre-menopausal females have reduced systemic inflammation 
compared to age-matched men, suggesting that estrogen may protect against 
inflammatory diseases such as cardiovascular events [7, 8].  Nevertheless, this protection 
against inflammation is lost in females after menopause. In fact, Lobo et al. showed that 
up to 40% of post-menopausal females may have metabolic syndrome, a syndrome that is 
associated inflammation and insulin resistance [57]. However, researchers demonstrated 
that post-menopausal females who used hormone-replacement therapy transdermally, had 
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a significant decrease in serum inflammatory markers [58]. In addition to the noted sex 
differences in inflammation, estrogen may also modulate oxidative stress and protect 
females from insulin resistance.  
 Oxidative stress is the state where reactive oxygen species (ROS) accumulate and 
the ability to dismiss the increased ROS becomes hindered. This disturbance in the redox 
state can affect tissues and promote further cell, DNA, and protein damage through the 
production of peroxides and free radicals [59]. Current published literature aimed at 
determining if males exhibit higher levels of oxidative stress compared to females is 
limited. However, in various clinical trials, lipid peroxidation has been utilized has a 
marker for oxidative stress. Lipid peroxidation is the process where free radicals, such as 
reactive oxygen species, steal electrons from lipids in the cell membrane creating a lipid 
radical. This lipid radical is now also a reactive oxygen species and can further augment 
oxidative stress by causing cell damage by attacking DNA and other cellular proteins 
[60].  In many studies, when compared to females, males have exhibited higher markers 
of oxidative stress, as measured by increased markers of lipid peroxidation [61-63]. 
Moreover, post-menopausal females have displayed increased levels of lipid peroxidation 
compared to pre-menopausal females and post-menopausal females supplemented with 
estrogen [63]. For instance, a clinical trial that combined estrogen and exercise in post-
menopausal females observed a significant reduction in the oxidation of high-density 
lipoprotein (HDL) compared to sedentary post-menopausal female who did not receive 
estrogen [64]. However, clinical trials have also produced contradictory data in regards to 
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sex differences in oxidative stress. For example, Ll’yasova at el. observed higher levels 
of lipid peroxidation in the urine of non-diabetic females compared to males [65].  These 
discrepancies could be due to the differences in the selected indicator of lipid 
peroxidation. Thus, the role of estrogen in the sex differences in oxidative stress is still 
unknown.  
Studies suggest that estrogen has protective effects against inflammation and 
oxidative stress. However, it is not clear if estrogen modulates inflammation and 
oxidative stress by an indirect mechanism (affecting adiposity) or a direct mechanism.  
 
1.3.3 Evidence from Experimental  Studies 
 Studies focused at understanding the differences in susceptibility to inflammation 
and oxidative stress between males and females include both in vivo and in vitro 
experimental models. Most of the in vivo studies have been conducted in mice fed a high 
fat diet [66, 67].  The in vitro models used to study the effects of estrogen on the 
expression of pro-inflammatory markers have included immune, neural and endothelial 
cells [68, 69]. 
 The data generated from animal studies on the effects of estrogen and 
inflammation is not clear; however, most studies appear to support the notion that 
estrogen has strong anti-inflammatory effects. For example, Payette C et al. showed that 
female mice consuming a high-fat diet had lower serum levels of IL6, TNFα, and C-
reactive protein compared to male mice [67]. Moreover, investigators have hypothesized 
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that the observed sex differences in inflammation may affect the susceptibility to other 
disease such as cancer. Indeed, Naughler et al. discovered that intact female mice were 
protected from chemically induced liver cancer due to their lower IL6 expression levels. 
This observation was further confirmed by the low liver cancer incidence in IL6 null 
mice [70]. After further investigation, researchers determined that estrogen was 
mediating this protective effect by modulating inflammation [71]. The above findings 
suggest estrogen may directly modulate inflammation. In support of this notion, in vitro 
studies, have established a role for estrogen in decreasing pro-inflammatory cytokines via 
the ERα pathway in neural cells [72, 73]. It is worth mentioning that activation of ERα by 
estrogen can lead to genomic and non-genomic signaling [74]. It is not clear if the anti-
inflammatory effects of estrogen are mediated via its genomic or non-genomic effects. 
Nonetheless, it has been shown that estrogen can interact with ERα and modulate the pro-
inflammatory signaling pathway, nuclear factor kappa B (NFĸB) [69, 75, 76]. However, 
the relationship between ERα and NFĸB is still unclear and is dependent on cell type [77-
79]. Additionally, studies have suggested that estrogen may mediate its anti-inflammatory 
effects via its effects on non-genomic signaling, such as the phosphatidylinositol 3-kinase 
(PI3K) pathway. Ghislettie et al. demonstrated that estrogen activated the PI3K pathway 
and inhibited NFĸB nuclear translocation in macrophages that were activated by 
lipopolysaccharides (LPS) [69]. The previously mentioned studies have mostly been 
conducted in neural and immune cells, so it is important to note that the anti-
inflammatory effects of estrogen can depend on the cell type, and the manner of how 
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estrogen is administered. For example, Calippe et al. used mouse peritoneal macrophages 
and showed that 10nM estrogen promoted Akt phosphorylation and diminished LPS-
induced cytokine production [80]. Moreover, Calippe et al. also showed that estrogen 
administration to ovx-female mice promoted inflammation as evidenced by increased 
expression of pro-inflammatory markers IL1-β, IL6, IL12 and inducible NO synthase 
(iNOS) in peritoneal macrophages exposed to LPS ex vivo [80].  The above discrepancies 
might be explained by the difference in estrogen concentration and exposure used in both 
the peritoneal macrophages and ovx-female mice; both are above physiological levels. 
Thus, there is a limited understanding of the anti-inflammatory role of estrogen 
specifically in adipocytes at physiological relevant levels.  
As noted earlier, there is limited epidemiological evidence supporting sex 
differences in oxidative stress; however, there is mounting evidence supporting the notion 
that estrogen is protective against oxidative stress [81]. Furthermore, it has been 
established that estrogen can decrease systemic ROS and inflammation in endothelial 
cells and protect against atherosclerosis [82, 83]. For example, Wagner et al. studied the 
effects of estrogen on human endothelial cells and found that treatment with estrogen 
caused a time and concentration-dependent reduction  in the expression of the NADPH 
oxidase subunit gp91phox [83]. NADPH oxidase subunits include gp91phox, p22phox, 
p40phox, p47phox, and p67phox and they are capable of producing superoxide by 
transferring electrons from NADPH inside the cell across the membrane and coupling 
these to molecular oxygen, thus contributing to oxidative stress. For instance, research 
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has provided support that NADPH oxidase is a major source of ROS production in 
endothelial cells, specifically O2
-
 , which plays an important role in the development of 
atherosclerosis [84, 85]. Atherosclerosis is defined as the chronic inflammation of the 
blood vessels caused by the accumulation of macrophages and promoted by low-density 
lipoproteins (LDL). Briefly, in regards to oxidative stress, high levels of ROS can oxidize 
LDL and cause the formation of foam cells, which then recruit macrophages that are 
unable to process the damaged cells and ultimately rupture causing the development of 
plaque and atherosclerosis. Researchers have provided additional insight to the role of 
estrogen and LDL-oxidation in endothelial cells. For example, Monsalve et al. utilized 
human endothelial cells exposed to oxidized LDLs and observed an increase in oxidative 
stress markers. However, when 1nM estrogen was incubated with the endothelial cells 
and oxidized LDL, researchers determined that estrogen was able to reverse the 
deleterious effects of oxidized LDL [86]. Therefore, antioxidant properties of estrogen 
could be essential to protecting female mice from adipocyte oxidative stress. 
1.3.3 The role of Estrogen in Adipocyte Inflammation and Oxidative Stress 
 There is little evidence regarding the effects of estrogen on inflammation and 
oxidative stress in adipose tissue.  However, as previously noted, estrogen has a potent 
effect on adipocyte morphology; therefore, it is feasible to assume that the anti-
inflammatory and antioxidant abilities of estrogen observed in neural and endothelial 
cells may also be observed in adipocytes.  
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 There is limited research designed to test the effects of estrogen on adipocyte 
inflammation and oxidative stress.  However, there are studies supporting the notion that 
compounds that have estrogenic properties have anti-inflammatory and antioxidant 
properties. For example, Pinent et al. tested the ability of isoflavones to reduce 
inflammation in 3t3L1 adipocytes [87]. Isoflavones have been known to have some of the 
protective properties of estrogen and thus are categorized as phytoestrogens or plant-
derived estrogens.  Moreover, since isoflavones resemble estrogen in their chemical 
structure, they can have both estrogenic and anti-estrogenic effects [88].  Briefly, Pinent 
et al. observed that isoflavones were able to decrease markers of inflammation in 3t3L1 
adipocytes, specifically prostaglandin E2 and IL6 [87]. However, the role of estrogen in 
adipocyte inflammation and oxidative stress is limited and should be evaluated further.  
1.4 Sex differences in measures of insulin resistance 
 1.4.1 Review of Epidemiological Studies 
Insulin resistance is defined as a physiological condition in which insulin is unable to 
mitigate a reduction in blood glucose levels. Insulin sensitive cells such as muscle and fat 
cells require insulin in order to absorb glucose, but in the case of insulin resistance this 
does not occur and results in hyperglycemia.  Because insulin is unable to promote a 
reduction in blood glucose levels, the pancreas continues to secrete insulin in order to 
alleviate the hyperglycemia, which leads to high circulating insulin, also known as 
hyperinsulinemia. Insulin resistance can be measured through various techniques which 
include but are not limited to glucose tolerance test (GTT), insulin tolerance test (ITT), 
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and the hyperinsulinemic euglycemic clamp. At the cellular level, investigators can also 
determine insulin resistance by analyzing components of the insulin signaling pathway.  
 Studies suggests that women are more insulin-sensitive than males [89]. Otsuki et 
al. showed that non-diabetic females had a higher sensitivity to insulin than non-diabetic 
males [90]. Furthermore, researchers have shown that if a post-menopausal female is 
already overweight or obese prior to menopause, then she is at an increased risk for 
developing insulin resistance [91]. Studies regarding the use of HRT and its abilities to 
improve insulin sensitivity in post-menopausal females are controversial. For example, 
Saglam et al. utilized insulin resistant post-menopausal females to determine the effects 
of HRT on insulin resistance. Their results showed that HRT was able to improve insulin 
sensitivity as evidenced by the decrease in serum insulin levels, thus indicating that HRT 
could be a possible therapeutic method in aiding insulin resistance in post-menopausal 
females [92]. However, others have shown that HRT can augment the state of insulin 
resistance in post-menopausal females. For instance, Ryan et al. observed that obese post-
menopausal females taking oral estrogen HRT were more insulin resistant compared to 
obese post-menopausal females not taking any HRT [93]. The discrepancies in these 
studies may be explained by the difference in the delivery of the HRT. A few studies 
have compared the different methods of HRT and have found that oral HRT can increase 
markers of inflammation and thus indirectly increase the risk of insulin resistance 
compared to transdermal HRT [94, 95].    
1.4.2 Review from Experimental Studies 
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 To establish the role estrogen has in regulating insulin sensitivity, investigators 
have used both in vivo and in vitro models. Mouse models have been very useful, 
especially transgenic mouse models that are altered to exhibit reduced estrogen signaling 
or endogenous estrogen. In vitro models have primarily focused on the effects of estrogen 
on hepatic insulin sensitivity and pancreatic cells.  
 ERαKO and ArKO female mice exhibit impaired glucose tolerance and insulin 
resistance. For example, Heine et al. performed a glucose tolerance test in both male and 
female ERαKO mice and found that both sexes had impaired glucose tolerance. However, 
in the wild-type mice, the female mice were able to restore their blood glucose levels 
back to baseline [32]. Moreover, ArKO mice, which have reduced endogenous estrogen 
levels, also displayed insulin resistance [96, 97]. Studies conducted in wild-type mice 
have also been useful in dissecting the role of estrogen in insulin sensitivity. For instance, 
Macotela et al. isolated perigonadal adipocytes from male and female mice and exposed 
the adipocytes to insulin ex vivo and their results showed that female adipocytes were 
more responsive to insulin compared to male adipocytes.  Macotela et al. treated 
adipocytes with estrogen and saw an increase in ERK and AKT phosphorylation, thus 
providing a potential mechanism by which estrogen may increase insulin sensitivity [98]. 
Furthermore, it has been suggested that estrogen treatment can increased insulin 
sensitivity in adipocytes by increasing the number of insulin receptors present on these 
cells [99]. Since the liver and pancreas are important in regulating the actions of insulin, 
researchers have deciphered the effects of estrogen on processes related to insulin 
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sensitivity in these tissues.  For example, investigators used ovx-female mice 
supplemented with estrogen and progesterone and found that ovx-female mice not 
receiving these hormones had higher blood glucose levels. After further experimentation, 
it was concluded that this observation was due to the abilities of estrogen to hinder 
hepatic gluconeogenesis and glycogenolysis [100]. Furthermore, the insulin sensitizing 
abilities of estrogen may also be due to its effects on pancreatic cells. Alonso-Magdalena 
et al. found that both estrogen receptors, ERα and ERβ, were present in pancreatic beta-
cells. Also, after exposing the pancreatic beta-cells to physiological levels of estrogen, 
the insulin content of the pancreatic beta-cell was increased due to increased gene 
expression [101]. Moreover, using both ERαKO and ArKO mice, researchers observed 
increased apoptosis in their pancreatic beta-cells, thus suggesting that estrogen may be a 
protective factor for pancreatic beta-cells [102]. Interestingly, both ERα and ERβ have 
been identified in skeletal muscle and researchers have shown that both can augment 
GLUT4 translocation to the cell membrane [103, 104]. In summary, researchers have 
established that estrogen has a beneficial effect on insulin sensitivity and that it mediates 
these effects via ERα and ERβ. 
 1.4.3 The role of estrogen in measures of insulin resistance 
As discussed above, estrogen protects agains insulin resistance, and the evidence suggest 
that estrogen mediates this protection via ERα and ERβ in multiple insulin sensitive 
tissues [100, 101, 103, 105]. However, it is important to note that the effects of estrogen 
on insulin sensitivity may be confounded by the fact that estrogen can protect agains 
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obesity.  For example, studies have shown that the increased visceral adiposity observed 
in males contributes to their state of insulin resistance and that pre-menopausal females 
are protected from insulin resistnace indirectly by their reduced visceral adipose tissue 
[89]. Thus, it is feasible that estrogen can further promote insulin sensitivity by 
decreasing body fat levels in the whole organism.   
1.5 The relationship between adipocyte morphology, inflammation, oxidative stress 
and measures of insulin resistance. 
 Obeisty is strongly associated with low-grade inflammation and oxidative stress, 
and all morbidities can play an important role in the development of insulin resistance 
[106-109] Moreover, obese adipose tissue is characterized by enlarged adipocytes, 
increased macrophage infilitration, increased oxidative stress, and increased pro-
inflammatory cytokine production [106, 107, 110-112].  For instance, Xu et al. and 
Weisberg et al. showed that obese adipose tissue has increased macrophage infiltration 
and elevated mRNA expression levels of numerous macrophage-related inflammatory 
genes. [113, 114]. Given that macrophages are well known phagocytes, investigators 
have suggested that the high number of macrophages in obese adipose tissue could play 
an important role in the remodling the obese adipose tissue by removing necrotic fat 
cells. For example, macrophages have been shown to cluster around necrotic adipocytes 
forming crown-like structures (CLS) in obese adipose tissue [111, 112, 115, 116]. In 
support of this idea, researchers have utilized transgenic models of inducible lipoatrophy 
and demonstrated that massive adipocyte death causes the recruitment of macrophages 
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[117]. Thus, the purpose of adipocyte infilitrating macrophages may be to removed fat 
cells that are damaged or are in the process of dying from necrosis or apoptosis [117].  
 Enlarged adipocytes can become necrotic or apoptotic for numerous reasons; 
however, a particular cause is oxidative stress due to hypoxia and endoreticulum (ER) 
stress. As adipose tissue expands it creates areas of hypoxia and the adipose tissue 
becomes poorly oxygenated and thus induces several pro-inflammatory pathways and 
promotes necrosis of the adipocyte [118-120]. Moreover, as excess nutrients continue to 
expand the enlarged adipocye, the ER reaches a stress threshold that activates the unfoled 
protein response (UPR). UPR is a signal for apoptosis and further augments the alreadly 
inflammaed milieu of the obese adipose tissue.  
 The low-grade pro-inflammatory enviroment observed in obese adipose tissue 
promoted by the recruited marcrophages due to the hypertrophic and stressed adipocytes, 
can be further aggrevated by the altered fatty acid flux of the adipocytes. Free fatty acids 
(FFA) are stored in expanding adipocytes in the form of triglycerides; however, under 
stressful signals, adipocytes can release FFAs in a process known as lipolysis. These 
FFAs can be used in numerous processes. For example, they can be shunted to the liver 
or skeletal muscle and used for oxidation. Or, in the case of obesity, they can be re-
esterfied and stored in nearby adipocytes [121, 122]. However, if the FFAs are not re-
esterfied and remain in the adipose tissue, they can promote a pro-inflammatory 
enviroment by activating the Toll-like receptor 4 (TLR4) signaling pathway [123]. 
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Specifcally, saturated FFAs can activate TLR4, which causes the translocation of nuclear 
factor kappa beta (NFĸβ) and thus increases the expression of IL6 and TNFα.  
In summary, the effects of obesity on adipose tissue expansion include increasing 
aidpocyte number and size. Evidence suggests that enlarged adipocytes increase 
production of pro-inflammatory cytokines due to marcopahge infiltration, oxidative 
stress, and accumulated free fatty accids. Elevated pro-inflammatory cytokines not only 
act locally but can have deleterious effects systemically. Numerous studies have shown 
that pro-inflammatory markers promote insulin resistance. For instance, Kamei et al. 
generated a transgenic mouse model that overexpressed MCP-1 in the adipose tissue 
[124]. These mice exhibited increased macrophage infiltration in the adipose tissue and 
insulin resistnace as evidenced by an insulin tolerance test [124]. Moreover, researchers 
have also found that TNFα and elevated FFAs can promote insulin resistance by 
activating the JNK pathway and by inhibiting the activation of IRS-1, which is necessary 
for insulin to activate the translocation of GLUT-4 to the cell membrane [125-127]. 
1.6 Summary and Persepective 
 Obesity is a disease that is associated with increased markers of inflammation, 
oxidative stress, and insulin resistance. Moreover, the protective effects of estrogen 
against the susceptibility to obesity may provide insight to the beneficial abilities of 
estrogen on the above morbidties. As discussed previously, it has been established that 
estrogen decreases the enlargement and formation of adipocytes; however, the 
mechanism behind this action is not well established. Furthermore, the anti-inflammatory 
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and antioxidant effects of estrogen are limited to studies conducted in immune, neural or 
endothelial cells and there is little established data concerning these abilites of estrogen in 
adipocytes. Finally, it is important to establish how the effects of estrogen on adipocyte 
morhphology and adipocyte inflammation and oxidative stress will affect markers of 
insulin resistance. Therefore, in this dissertation, we hypothesize that estrogen regulates 
obesity associated inflammation, oxidative stress and insulin resistance through 
modulation of adiposity.  
 
Chapter 2 will assess the effects of estrogen on abdominal adiposity and glucose 
tolerance in female mice.  
Chapter 3 will determine the abilities of estrogen to modulate adipocyte size and protect 
female mice from markers of adipose tissue inflammation and oxidative stress, and 
insulin resistance.  
Chapter 4 will investigate the anti-inflammatory and anti-oxidant effects of estrogen in 
3t3L1 adipocytes.  
Chapter 5 provides a summary and directions for future research.   
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Chapter 2: Estrogen modulates abdominal adiposity and protects female 
mice from obesity and impaired glucose tolerance 
The material presented in this chapter is published in a paper titled “Estrogen modulates 
abdominal adiposity and protects female mice from obesity and impaired glucose 
tolerance”[128].  
Abstract 
Obesity increases the risk of diabetes. The dysregulation of estrogen metabolism 
has been associated with the susceptibility to obesity and diabetes. Here, we explore the 
role estrogen plays in sex differences in obesity and glucose metabolism, specifically 
adipocyte biology. We randomized C57BL/6J male, non-ovariectomized female, 
ovariectomized female and ovariectomized female mice supplemented with 17β estradiol 
to receive a calorie-restricted, low or a high fat diet (15 mice per group). We measured 
weight gained, calories consumed, percent body fat, abdominal adipose tissue, adipocyte 
size, lipogenic and adipogenic gene expression and glucose tolerance. Our results show 
that male mice had a higher susceptibility to obesity than intact female mice. However, 
removal of the ovaries in female mice eliminated the protection to obesity and estrogen 
supplementation restored this protection. Male and ovariectomized female mice gained 
weight predominately in the form of abdominal adipose tissue possibly due to an increase 
in adipocyte size. Moreover, for mice consuming the high fat diet, male and 
ovariectomized female mice had significantly higher levels of leptin mRNA and lower 
hormone-sensitive lipase mRNA relative to intact female mice and ovariectomized 
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female mice supplemented with estrogen. Additionally, estrogen had a strong inhibitory 
effect on key adipogenic genes in non-ovariectomized female and ovx-female mice 
supplemented with estrogen. Finally, we show that male and ovariectomized female mice 
consuming the high fat diet had a higher incidence of glucose intolerance. In conclusion, 
estrogen protects female mice from obesity and impaired glucose tolerance possibly by 
modulating the expression of genes regulating adipogenesis, lipogenesis, and lipolysis. 
Introduction 
 The incidence of obesity has grown at an epidemic rate at both a national and 
global level [129].  One-third of Americans are considered to be obese, which is defined 
as a body mass index (BMI) of >30kg/m².  Obesity increases the risk of numerous 
diseases, such as diabetes mellitus (type 2 diabetes). The role sex plays in the 
susceptibility to obesity is not fully understood, specifically the role of ovarian hormones 
in response to different amounts of caloric consumption.  Previously, our lab 
demonstrated that male mice were more likely to become obese compared to novx-female 
mice [25]. Furthermore, it has been established that the protection against obesity in 
female mice is eliminated by ovariectomy (surgical removal of the ovaries) and can be 
reversed through the administration of estrogen [130-132].  Various mouse models have 
been used to assess the significance of estrogen in the regulation of abdominal adiposity. 
In both ERαKO and ARKO mice, results show that a decrease in systemic estrogen levels 
and signaling can cause a significant increase in abdominal adiposity [32, 36, 133]. 
Moreover, estrogen has been shown to decrease food consumption and promote energy 
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expenditure, thus creating a negative energy balance and preventing obesity [28, 134, 
135]. The role of estrogen in the regulation of lipogenesis is unclear. Previous research 
has shown that estrogen suppresses lipoprotein lipase (LPL) transcription possibly due to 
an estrogen response element that is located in the promoter region of this gene [38]. 
Moreover, others have established that estrogen stimulates lipolysis in adipocytes 
possibly through the regulation of perilipin [27]. The effect of estrogen in adipogenesis is 
still convoluted and needs further exploration. Specifically, it has yet to be determined 
whether estrogen affects the early or late events of adipogenesis and if it is modulating 
key adipogenic genes, such has peroxisome proliferator-activated receptor-gamma 
(PPARγ), ccaat-enhancer-binding proteins (CEBPβ), and lipin1. PPARγ and CEBPβ are 
key transcription factors that are highly regulated during adipogenesis and lipin1 has 
recently been shown to be essential for adipocyte development [136-138]. Adipocyte 
biology has the ability to affect many physiological processes, particularly glucose 
metabolism. Our laboratory and others have demonstrated that the higher susceptibility to 
obesity in male mice is associated with a higher propensity of becoming insulin resistant 
[139, 140].  Moreover, studies have identified a significant correlation between small 
adipocyte size and improved insulin sensitivity in female mice [98]. However, it is not 
clear how estrogen modulates the adipocyte biology process and how these differences 
may affect other morbidities. Thus, the objective of the present study is to determine if 
estrogen can protect female mice from obesity and its morbidities by modulating key 
genes involved in adipocyte biology. 
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  To determine the role of estrogen in the sex differences in the susceptibility to 
obesity and diabetes, we used the following groups of C57BL/6J mice in our studies: 1) 
males, 2) non-ovariectomized females (novx-females), 3) ovariectomized females (ovx-
females), and 4) ovariectomized females supplemented with estrogen (ovx-females+E2), 
which were randomized to receive one of three different diets: 15-30% calorie restricted, 
low fat or high fat diet (CR, LF, and HF). Our results show that when exposed to a high 
fat diet, male mice became obese sooner than female mice and that removal of the ovaries 
eliminated the protection against obesity in female mice. In fact, ovx-female mice weight 
gain patterned that of male mice.  However, supplementation of 17β-estradiol to ovx-
female mice restored the protection against obesity observed in novx-female mice. This 
difference in bodyweight was also reflected in body adiposity, specifically abdominal 
adiposity and adipocyte size. Estrogen also had a significant effect on lipogenic and 
adipogenic genes. Moreover, male and ovx-female mice consuming a high fat diet had 
significantly impaired glucose tolerance suggesting that males and ovx-females may have 
a higher susceptibility to become insulin resistance. This finding was further supported 
by the higher insulin and resistin serum levels observed in the male and ovx-female mice 
consuming the high fat diet.  
Materials and Methods 
 
 
Mouse husbandry and diets  
 A total of 195 pathogen free C57BL/6J male, non-ovariectomized female, 
ovariectomized female, and sham-ovariectomized female mice were purchased from 
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Jackson Labs (Bar Harbor, Maine, USA) at 6 weeks of age and housed according to NIH 
guidelines (National Research Council, 1996) in the Animal Resources Center at the 
University of Texas at Austin.  The animal protocol was approved by the Institutional 
Animal Care and Use Committee at UT-Austin.  The mice were singly housed and 
maintained on a 12hour light–dark cycle and at a temperature of 22-24°C.  After two 
weeks of acclimation, the mice were randomized, 15 mice per group, to receive one of 
three semi-purified diet regimens: 1) a 15-30% calorie restricted diet (CR; D03020702), 
2) a low fat diet (LF; 10% fat from kcals, D12450B), and 3) a high fat diet (HF; 60% fat 
from kcals, D12492).  To control for the effects of surgery on bodyweight and glucose 
metabolism, we included sham-ovariectomized female mice who consumed the low fat 
diet (n=15). All diets were obtained from Research Diets, Inc. and are semi-purified diets 
(New Brunswick, NJ, USA).  A table with detailed information on these diets was 
previously described [141].  Briefly, the fiber content is identical in all three diets (50g), 
and the caloric content is identical in both the CR and LF diet (3.8kcal/g), but the HF diet 
is hypercaloric (5.2kcal/g). The CR diet was modified so that the mice received 70-85% 
(2.7g/day) of the mean daily caloric consumption of their respected control (LF) group, 
but 100% of the vitamins and minerals. Mice were fed ad libitum or calorie-restricted; 
body weight, food, and liquid consumption were recorded weekly. All mice, including 
the sham-ovariectomized mice, were sacrificed after 10 weeks.  
Estrogen supplementation 
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 To further characterize the role estrogen plays in the susceptibility to obesity and 
glucose metabolism, we implanted a 0.72mg 17β estradiol pellet into ovariectomized 
female mice, which delivered 5μg/d (Innovative Research of America, Sarasota, USA).  
This dosage protocol is similar to the estradiol supplementation used by others and has 
been shown to re-establish physiological estradiol levels in ovariectomized female mice 
[142]. Control mice were implanted with placebo pellets.  At 9 weeks of age, 
ovariectomized mice were randomized to receive either a placebo or an estradiol pellet.  
Mice were anesthetized with isoflurane, the dorsal area between the ear and shoulder was 
shaved and sterilized with 70% isopropyl alcohol, and a trochar was used to implant the 
4.5 mm pellet subcutaneously.  
Body composition 
 Body composition was determined using magnetic resonance imaging (MRI), 
specifically, the EchoMRI QNMR from Jackson Labs (Bar Harbor, Maine, USA).  This 
device allowed us to measure lean mass, percent body fat and water content without 
sedating the mice.  
Assessment of abdominal adiposity 
 After necropsy, all mice were thawed at room temperature and visceral adipose 
tissue was removed from the entire abdominal cavity of the mouse and weighed. The 
abdominal fat depots collected included gonadal, perirenal and omental fat pads. The 
percent abdominal fat represents the total weight of the abdominal adipose tissue divided 
by the total weight of the mouse.  
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Assessment of other adipose tissue depots 
 After necropsy and the removal of all abdominal adipose tissue, the remaining 
adipose tissue content was determined by dual-energy X-ray absorptiometry (DEXA) 
using a GE Lunar Piximus II densitometer (Madison, WI, USA).  The percent of other 
adipose tissue depots represents the weight of the remaining adipose tissue after the 
removal of the abdominal fat determine by DEXA divided by the final body weight.  
Measurement of adipocyte size 
 At necropsy, perigonadal adipose tissue was fixed in 10% neutral buffered 
formalin for 48 hours and then transferred to 70% ethanol indefinitely.  Adipose tissue 
was paraffin-embedded and cut 5μm thick.  For histological analysis, tissues were 
hematoxylin and eosin-stained.  The size of the adipocytes was determined using Nikon’s 
NIS Elements AR software (Melville, N.Y, USA). Eight samples from each group were 
randomly selected for analysis.   
QRTPCR 
 Total RNA was extracted from frozen white adipose tissue using an RNAeasy 
Mini Kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. RNA 
content was determined by measuring the absorbance at 260 and 280 nm. Reverse 
transcription was conducted with a High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA), using 2μg of RNA for each reaction. Real time 
PCR was performed with a SYBR GreenER qPCR kit (Invitrogen, Carslbad, CA) and a 
Mastercycle Realplex Thermocycler (Eppendorf, Hamburg, Germany). The relative 
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expression level of each target gene was normalized to the endogenous reference control 
gene 18s rRNA. Moreover, the male mice were used as the calibrator to which all other 
groups were compared against using the CT method. The primers are available upon 
request. 
Glucose tolerance test 
 To establish the role of estrogen in glucose metabolism, ten randomly selected 
mice were fasted for 14 hours and then intraperitoneally injected with 20% glucose, 
2g/kg of bodyweight. Blood glucose was measured using a Glucometer Elite (Bayer, 
Elkhart, IN). Approximately half a drop of blood was drawn from each mouse tail.  Blood 
glucose levels were measured at 0, 15, 30, 60, and 120 minutes from injection time and 
area under the curve was calculated.  
Measurement of serum hormones 
 In order to assess the sex differences in serum hormone levels, we measured 
serum levels of leptin, insulin and resistin in high fat fed mice. Mice were fasted three 
hours prior to necropsy and serum was collected. Serum leptin, insulin, and resistin were 
detected using Millipore’s Milliplex Map Mouse Serum Adipokine Panel (Billerica, 
MA). 
Statistics 
 To determine the effects of both diet and sex, results were analyzed by ANOVA 
with pairwise comparisons and a post-hoc comparison of means using Tukey’s Honestly 
Significant Difference.  All results are presented as mean ± standard error mean (S.EM).  
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SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for all 
statistical comparisons.  P-values ≤ 0.05 were considered statistically significant.  
Results 
Sex differences in bodyweight 
 The three different diet regimens (CR, LF, and HF) induce three different body 
phenotypes (lean, overweight, and obese).  Figure 2.1 shows the body weights induced by 
the diets.  There were no significant differences in body weights in the CR groups.  In the 
LF groups, male and ovx-female mice weighed significantly more compared to novx-
female and ovx-female+E mice (p<0.05).  After 10 weeks of consuming a high fat diet, 
male mice weighed significantly more than novx-female mice (39.7 ± 0.95 vs. 26.8 ± 
1.2g, p < 0.001).  Moreover, when the ovaries were removed, the ovx-female mice 
mimicked male mice in their weight gain (37.1 ± 0.87g, p<0.001).  However, estrogen 
supplementation restored the protection against obesity, and ovx-female+E mice 
resembled the body weight of novx-female mice (24.6 ± 1.0g, p<0.001).     
Food consumption  
 To determine if the differences in bodyweight were due to differences in food 
consumption, the average daily caloric intake (kcal/d) was assessed for each group.  This 
data is presented in Table 2.1.  As expected, caloric consumption between CR, LF and 
HF groups was significantly different; CR consumed the least amount of calories and HF 
consumed the most. All of the mice received the same amount of calories per day in the 
CR groups. In the groups consuming the low fat diet, there were no significant 
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differences in calorie consumption between novx-female, ovx-female, ovx-female+E 
mice. In the mice consuming the high fat diet, calorie consumption was not significantly 
different between male, novx-female and ovx-female mice.  
Estrogen alters body composition by modulating abdominal adiposity 
 Figure 2.2 shows the sex differences in adipose tissue deposition. Panel A 
represents abdominal adiposity.  Overall, there was a diet interaction within each gender, 
with CR mice displaying the least amount of abdominal adiposity and HF mice 
displaying the most abdominal adiposity. However, after ten weeks on the high fat diet, 
male and ovx-female mice had significantly higher body fat levels compared to novx-
female and ovx-females+E2 mice (9.67±0.54% and 11.41±0.27% vs. 6.99±0.8% and 
2.86± 1.28%, respectively, p<0.001).  Panel B represents the percentage of other adipose 
tissue depots, which primarily consists of subcutaneous adipose tissue. There were no 
significant differences in these adiposity levels between male, novx-female and ovx-
female mice; however, ovx-female+E mice had lower other adiposity levels compared to 
the other groups. Panel C represents total adiposity. Within the high-fat diet group, male 
and ovx-female mice had significantly higher levels of total adiposity compared to novx-
female and ovx-female+E mice (36.6 ± 1.9% and 50.1 ± 1.2 % vs. 24.3 ± 3.6% and 17.2 
± 4.2 %), respectively, p <0.001. Our results suggest that the difference in adiposity 
identified between the sexes is due to alterations in abdominal adiposity.  
Estrogen decreases adipocyte size  
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 To determine if this increase in abdominal adiposity was due to adipocyte 
hypertrophy, we assessed adipocyte size.  Results in Figure 2.3 show CR mice had the 
smallest, LF had the intermediate, and HF mice had the largest adipocytes.  We also 
found a strong relationship between sex and adipocyte size.  When exposed to a high fat 
diet, male mice had significantly larger fat cells compared to novx-female mice 
(p<0.001).  However, removal of the ovaries in female mice made the size of the fat cells 
between male and ovx-female mice similar.  Treatment of ovx-female mice with estrogen 
significantly decreased the size of their fat cells (p<0.001), which tended to be of similar 
size or smaller than those found in novx-female mice.  Moreover, in groups consuming 
the low fat diet, ovx-female mice had significantly larger adipocytes compared to novx-
female and ovx-female+E mice (p<0.001).  
Sex differences in lipogenic, lipolytic and adipogenic gene expression 
 To gain a better understanding of the role of estrogen in the expression of 
adipogenic genes we measured their mRNA levels. As a positive control, we measured 
leptin mRNA levels, which have been shown to correlate with total adiposity [10]. We 
selected to detect the expression of adipogenic genes only in the mice consuming the high 
fat diet, because in this group of mice we observed the most drastic increases in 
adiposity. Briefly, we found that similar to the total adiposity levels, male and ovx-female 
mice had significantly higher leptin mRNA levels relative to novx-female and ovx-
female+E mice, p<0.05. In addition, we measured mRNA levels of lipoprotein lipase 
(LPL) and hormone sensitive lipase (HSL). There was no significant difference in LPL 
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mRNA levels, but novx-female (2.5x) and ovx-female+E mice (2.76x) had significantly 
higher mRNA levels of HSL compared to male and ovx-female mice, Figure 2.4. Results 
also show that ovx-female mice had significantly higher PPARγ mRNA levels compared 
to novx-female and ovx-female+E mice (1.3x vs. -2.79x and -4.63x, respectively, 
p<0.05). Moreover, male mice had significantly higher mRNA levels of cebpβ compared 
to novx-female and ovx-female+E mice. Interestingly, estrogen had a strong effect of 
lipin1 mRNA levels. Novx-female and ovx-female+E mice had significantly lower 
mRNA levels compared to male mice (-15.76x and -10.89x vs. 1x, respectively, p<0.05), 
Figure 2.5.  
Estrogen protects female mice from glucose intolerance 
 To determine if there were sex differences in the susceptibility to diabetes we 
conducted a glucose tolerance test.  Briefly, Figure 2.6A shows that male mice were 
glucose intolerant (glucose disappearance rate was lower) compared to novx-female 
mice, and removal of the ovaries caused the female mice to mimic the glucose 
intolerance observed in the male mice.  However, supplementation with estrogen to the 
ovx-female mice improved their glucose tolerance to levels similar of novx-female mice. 
Figure 2.6B, is a graphical representation of the calculated area under the curve for the 
glucose tolerance test.  
Sex differences in serum hormone levels 
 To assess the systemic effects of estrogen on serum hormone levels, we measured 
serum leptin, insulin and resistin in mice consuming the high fat diet. Briefly, in Figure 
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2.7A, we detected significantly higher serum leptin levels in male and ovx-female mice.  
These results are comparable to the leptin mRNA levels found in the adipose tissue of 
male and ovx-female mice. Moreover, in Figure 2.7B and 2.7C, we detected higher serum 
levels of insulin and resistin in the male and ovx-female mice, which is suggestive of 
insulin resistance and supports our findings of impaired glucose tolerance in the male and 
ovx-female mice.    
 
Discussion 
 The specific role estrogen plays in obesity and diabetes sex disparities is not 
completely understood. Our studies suggest male mice are more susceptible to obesity 
and impaired glucose tolerance due to an increase in abdominal adiposity secondary to 
adipocyte hypertrophy. Moreover, we show estrogen has a significant role in altering 
genes regulating adipogenesis, lipogenesis, and lipolysis and could therefore be a major 
player in the prevention of obesity and its co-morbidities.  
We propose that estrogen modulates central adipose tissue metabolism to protect 
female mice from the obesogenic effects of a high fat diet.  Our data confirm what others 
have shown: as body weight increases, percent body fat becomes elevated and adipocyte 
size expands [8].  Moreover, we observed that body composition was modulated by 
estrogen.  Briefly, our results show estrogen had a dramatic effect on abdominal 
adiposity. Others have shown that the effects of estrogen on adiposity occur 
predominantly in abdominal fat depots as opposed to subcutaneous fat depots [27]. 
Additionally, even though body weights between male and ovx-female mice were 
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similar, ovx-female mice tended to have more abdominal and subcutaneous fat depots.  
Furthermore, the adipocytes of ovx-female mice were larger than those of male mice and 
their adipocyte gene expression differed.  Specifically, ovx-female mice exhibited much 
lower cebpβ and lipin1 mRNA expression levels relative to male mice. Although not 
significant, mRNA expression levels were considerably decreased compared to male 
mice which might suggest sex differences in adipogenesis independent of estrogen. Male 
mice have more testosterone than ovx-female mice; on the other hand, as the male mice 
become obese, testosterone levels decrease which can contribute to the loss of lean body 
mass [143]. Furthermore, research has shown that low levels of testosterone in men and 
high testosterone levels in post-menopausal women increase their susceptibility to 
diabetes [144].  
It is well established that adipocyte size strongly correlates with the incidence of 
certain chronic diseases, such as diabetes [50, 145].  Small fat cells are strongly 
associated with insulin sensitivity independent of BMI [27].  Moreover, the expression of 
lipogenic genes is  inversely correlated with adipocyte size [146].  The presence of large 
adipocytes has been linked to the increased production of hormones and other bioactive 
substances, such as leptin, insulin, IGF-1, pro-inflammatory cytokines, and reactive 
oxygen species [147-149].  Our results show that when fed a high fat diet, the adipocytes 
of male and ovx-female mice increased in size which was accompanied by higher serum 
levels of leptin, insulin, and resistin. However, the adipocytes of novx-female and ovx-
female+E mice were resistant to enlargement, suggesting that estrogen could prevent the 
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increase in adipocyte size by possibly interfering with the expression of certain lipogenic 
genes [150].  In fact, our results show that estrogen increased HSL mRNA levels and 
others have demonstrated that estrogen inhibits lipogenesis through interactions with 
lipoprotein lipase [151, 152].  Our findings also imply a strong role for estrogen in 
adipogenesis as evidenced by significantly lower PPARγ, cebpβ, and lipin1 mRNA 
levels. PPARγ and cebpβ are key transcription factors shown to be essential in adipocyte 
development [153]. The Lipin1 gene is also essential for adipocyte development as mice 
deficient in lipin1 suffer from lipodystrophy and display hepatic steatosis [154]. 
Therefore, our data suggest that estrogen could be important in adipocyte development 
and as a result could play a significant role in protecting female mice from obesity and its 
co-morbidities.  
 Although estrogen has a prominent effect on genes regulating adipocyte 
morphology, it is important to note that estrogen could prevent obesity through other 
means. For instance, estrogen has been documented to increase physical activity by 
stimulating ERα in the hypothalamus [11].  Moreover, the removal of the ovaries can 
cause a drastic decrease in the metabolic rate of mice [28]. Additionally, studies have 
shown a potential role for ERβ in the prevention of obesity; therefore, this could be 
another alternative mechanism employed by estrogen to protect female mice from obesity 
[155]. Furthermore, estrogen also has a stimulatory role in lipid oxidation in both the 
liver and the muscle by up-regulating genes involved in lipid oxidation [156-158]. Thus, 
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it is conceivable that the positive effect of estrogen on energy expenditure could also play 
an important role in preventing obesity.   
 In summary, we show that estrogen protects female mice from obesity and 
impaired glucose tolerance by modulating genes regulating lipogenesis, lipolysis, and 
adipogenesis.  
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Figure 2.1 Sex differences in bodyweight (A) Mice were 
maintained on one of three different diet regimens (Calorie-
restricted (CR), Low-fat (LF), High-fat (HF)) for 10 weeks with 
n=15 per diet group.  * Significantly different compared to novx-
female and ovx-female+E mice in the low fat diet group, p<0.05 
(n=15). ** Significantly different compared to novx-female and 
ovx-female+E mice in the high fat diet group, p<0.001 (n=15). (B) 
Images were taken at the time of necropsy (Week 10) and were 
captured from mice exposed to a high fat diet. 
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 Table 2.1: Sex differences in food consumption. When 
exposed to a low-fat and high-fat diet, there was no significant 
difference in calorie consumption between novx-females and 
ovx-females.  *Significantly different compared to ovx-females 
and ovx-females+E. **Significantly different compared to other 
groups. 
 
 
 
 
Table 2.1: Average daily food consumption (kcal/d) 
  CR LF HF 
Males 7.9±0.0 11.5±0.2* 13.7±0.2 
Novx-females 7.9±0.0 10.2±0.2 12.9±0.7 
Ovx-females 7.9±0.0 9.8±0.1 12.8±0.2 
Ovx-females+E 7.9±0.0 9.2±0.2 11.1±0.4** 
P-Value P>0.05 P<0.05 P<0.05 
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Figure 2.2: Estrogen alters body composition by modulating abdominal 
adiposity (A) Sex differences in abdominal adiposity. (B) Represents other adipose 
tissue depots, which was assessed by DEXA after the complete removal of 
abdominal adipose tissue.  (C) Total body adiposity which was determined in 8 mice 
per group with a magnetic resonance imaging (MRI) machine. * Significantly 
different compared to novx-female and ovx-female+E mice within the low fat diet 
groups (n=8). ** Significantly different compared to novx-female and ovx-
female+E mice in high fat diet group, p<0.001 (n=8). + Significantly different 
compared to ovx-female mice consuming the low fat diet group, p < 0.05. ++ 
Significantly different compared to all other groups consuming the high fat diet, p < 
0.05.  
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Figure 2.3: Sex differences in adipocyte area. (A) Adipose tissue was collected 
from the perigonadal region of each mouse and stained with hematoxylin and eosin. 
Two images were taken from each slide at 10x magnification. (B) The average size 
of the fat cells for each group.  Adipocyte size was determined by Nikon’s NIS 
Elements AR software, scale bar equals 100μm. * Significantly different compared 
to novx-female and ovx-female+E mice consuming the low fat diet (n=7). ** 
Significantly different compared to novx-female and ovx-female+E mice in high fat 
diet group, p<0.001 (n=7). 
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Figure 2.4: Sex differences in lipogenic genes.  As a positive control, we measured 
leptin mRNA levels in the high-fat fed mice, which were consistent with adiposity 
levels. * Significantly different compared to novx-females and ovx-females+E with 
the same gene, P< 0.05. mRNA levels less than 1 are presented by their negative 
reciprocal. 
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Figure 2.5: Sex differences in adipogenic genes. To determine how estrogen 
affects key adipogenic genes we measured mRNA levels of PPARγ, cebpβ, and 
lipin1 from adipose tissue collected from the perigonadal depot of high-fat fed mice. 
* Significantly different compared to novx-female and ovx-female+E mice, p <0.05. 
** Significantly different compared to novx-female and ovx-female+E mice, p 
<0.05. + Significantly different come from ovx-female+E mice, p <0.05. MRNA 
levels less than 1 are presented by their negative reciprocal. 
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Figure 2.6: Estrogen protects female mice from impaired glucose tolerance. On the 10th week, GTT 
was performed after a 14hr fast. Mice were injected with 20% glucose and a small drop of blood was 
collected from the tail to measure blood glucose levels at 0, 15, 30, 60, 120 minutes after injection.  (A) 
After 10 weeks of consuming a high-fat diet, male and ovx-female mice experience significantly more 
glucose intolerant compared to novx-female and ovx-female+E mice. (B)Area under the curve was 
calculated. ** Significantly different compared to novx-female and ovx-female+E consuming the high fat 
diet, p<0.001 (n=10). *Significantly different compared to novx-female and ovx-female+E consuming the 
low fat diet, p<0.001 (n=10). 
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* 
Figure 2.7: Sex differences in serum hormone levels in high-fat fed mice. After three hours of fasting, 
serum was collected from the mice. Using mice consuming the high-fat diet, we detected serum leptin, 
insulin, and resistin levels using Millipore’s Milliplex Map Mouse Serum Adipokine Panel (Panels A, B,C, 
respectively). *Significantly different compared to novx-female and ovx-female+E mice consuming the 
high fat diet, p<0.05 (n=8). 
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Chapter 3: Estrogen alters adipocyte biology and protects female mice from 
adipocyte inflammation and insulin resistance 
The material presented in this chapter is published in a paper titled “Estrogen alters 
adipocyte biology and protects female mice from adipocyte inflammation and insulin 
resistance ” [159].  
Abstract 
 Obesity is associated with insulin resistance, liver steatosis, and low-grade 
inflammation. The role of estrogen in sex differences in the above co-morbidities is not 
fully understood. Our aim was to assess the role estrogen has in modulating adipocyte 
size, adipose tissue oxidative stress, inflammation, insulin resistance, and liver steatosis.   
To determine the role estrogen has in the above co-morbidities related to obesity, we 
randomized C57BL/6J mice into four groups (15 mice per group): 1) male, 2) non-
ovariectomized female (novx), 3) ovariectomized female (ovx), and 4) ovariectomized 
female mice supplemented with 17β estradiol (ovx-E).  Mice received either a low-fat or 
a high-fat diet for 10 weeks.  Outcomes measured were bodyweight, body fat, adipocyte 
diameter, adipose tissue lipolysis markers, adipose tissue oxidative stress, inflammation, 
insulin resistance, and liver steatosis. Our results show that male and ovx-female mice 
consuming the high-fat diet had a higher propensity of gaining weight, specifically in the 
form of body fat.  Estrogen protected female mice from adipocyte hypertrophy and from 
developing adipose tissue oxidative stress and inflammation. Moreover, novx-female and 
ovx-female+E mice had higher phosphorylated levels of PKA and HSL, markers 
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associated with lipolysis. Additionally, male and ovx female mice had a higher 
propensity of developing liver steatosis and insulin resistance.  In contrast, estrogen 
protected female mice from developing liver steatosis and from becoming insulin 
resistant.  In summary, we show that estrogen protects female mice from adipocyte 
hypertrophy and adipose tissue oxidative stress and inflammation.  Furthermore, estrogen 
prevented female mice from developing liver steatosis and from becoming insulin 
resistant. 
Introduction 
Obesity is a growing global epidemic that increases the risk of diabetes, cardiovascular 
disease, and metabolic syndrome [160]. Evidence supports the notion that the 
susceptibility to the above morbidities is modified by sex.  However, the specific role 
estrogen plays in the differential susceptibility to these morbidities between males and 
females is not well known. Others have established that estrogen protects female mice 
from becoming obese, and that this protection is mediated through the estrogen receptor-
alpha (ERα) [32, 133, 161].  On the other hand, it remains to be established if there are 
differences in adipocyte size, adipose tissue inflammation and oxidative stress between 
males and females, and more specifically how estrogen may modulate these biological 
parameters [162, 163].  
 Epidemiological studies show that premenopausal women are less likely to 
develop inflammation compared to age-matched men, suggesting that estrogen may 
protect against inflammatory diseases such as cardiovascular events [164, 165].  
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Moreover, studies show that postmenopausal women have a higher propensity of 
developing abdominal adiposity, which is associated with increased systemic levels of 
inflammatory cytokines, thus indicating that estrogen can modulate both body adiposity 
and systemic inflammation [58].  Evidence also implies that postmenopausal women 
have enlarged adipocytes and that the lipolytic activity in these adipocytes is high, which 
may explain why postmenopausal women have higher systemic levels of free fatty acids 
[27, 166].  Lipolysis is a tightly regulated process, which consists of the activation of key 
lipases. Upon phosphorylation by protein kinase A (PKA), adipose triglyceride lipase 
(ATGL) and hormone sensitive lipase (HSL) cleave free fatty acids off triacylglycerides, 
which are released into the blood.  Hyperlipidemia can promote drastic morbidities; for 
example, excess free fatty acids in the blood can accumulate in the liver and skeletal 
muscle, which can lead to an inflammatory environment and to the development of liver 
steatosis and insulin resistance [54, 55].  Excess accumulation of fatty acids in the liver 
can increase the risk of liver steatosis, which has been suggested to be a risk factor for 
liver cancer [167].  Differences in liver lipid metabolism between males and females may 
be one explanation why males have a higher propensity of developing liver cancer.  For 
instance, the global incidence of liver cancer is 2.4 fold greater in males compared to 
females [168].  Moreover, Naugler et al. showed that estrogen protects female mice from 
hepatocellular carcinoma by decreasing liver inflammation [70].  Furthermore, estrogen 
can indirectly protect female mice from liver cancer possibly by altering lipid 
metabolism.  Evidence suggests that estrogen can increase fatty acid oxidation, thus 
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decreasing the probability of fatty acids accumulating in skeletal muscle and in the liver 
[156, 169]. The objective of the present study was to determine if estrogen protects 
female mice from liver steatosis and insulin resistance by modulating adipocyte biology.  
Overall, our results show that estrogen not only protects female mice from obesity but 
also its co-morbidities, possibly through the modulation of adipose tissue and lipid 
metabolism.  
Materials & Methods 
Mouse husbandry and diets  
 A total of 135 pathogen-free C57BL/6J male, non-ovariectomized female, 
ovariectomized female, and sham-ovariectomized female mice were purchased from 
Jackson Labs (Bar Harbor, Maine, USA) at 6 weeks of age and housed according to NIH 
guidelines (National Research Council, 1996) in the Animal Resources Center at the 
University of Texas at Austin.  The animal protocol was approved by the Institutional 
Animal Care and Use Committee at UT-Austin.  The mice were singly housed and 
maintained on a 12-hour light–dark cycle at a temperature of 22-24°C.  Mice were 
randomized after two weeks of acclimation with15 mice per group, to receive a low-fat 
(LF) diet (10% fat, D12450B) or a high-fat (HF) diet (60% fat, D12492).  Sham-
ovariectomized mice were included to control for the effects of surgery on bodyweight 
and consumed the low-fat diet.  All diets were obtained from Research Diets Inc. (New 
Brunswick, NJ, USA).  A table with detailed information on these diets was previously 
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described [141].  Bodyweight, food and liquid consumption were recorded weekly and 
mice were fed ad libitum.  
Estrogen supplementation 
 To further characterize the role estrogen plays in adipocyte biology and 
inflammation, we implanted a 0.72mg 17β estradiol pellet into ovariectomized female 
mice, which delivered 5μg/d.  This dosage protocol is similar to the estradiol 
supplementation used by others and has been shown to re-establish physiological 
estradiol levels in ovariectomized females [142]. Control mice were implanted with 
placebo pellets.  At 9 weeks of age, ovariectomized mice were randomized to receive 
either a placebo or an estradiol pellet.  Mice were anesthetized with isoflurane. The dorsal 
area between the ear and shoulder was shaved and sterilized with 70% isopropyl alcohol 
and a trochar was used to implant the 4.5 mm pellet subcutaneously.  
Body composition 
 Body composition was assessed using magnetic resonance imaging (MRI), 
specifically, the EchoMRI QNMR from Jackson Labs (Bar Harbor, Maine, USA).  This 
device can measure lean mass, body fat mass and water content without sedating the 
mice. 
Measurement adipocyte diameter and quantification of gamma-H2AX 
 At necropsy, adipose tissue was collected from the intra-abdominal perigonadal 
fat pad, which others have shown to be metabolically significant in regards to adipocyte 
biology and inflammation [10[170]. Adipose tissue was fixed in 10% neutral buffered 
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formalin for 48 hours and then transferred to 70% ethanol indefinitely.  For histological 
analysis, adipose tissue was paraffin-embedded and cut 5μm thick and stained with 
hematoxylin and eosin. This procedure has been used in previous studies examining 
adipocyte biology [171, 172]. All samples were prepared simultaneously and under the 
same protocol.  The diameter of the adipocytes was determined using Nikon’s NIS 
Elements AR software (Melville, N.Y, USA). Eight samples from each group were 
randomly selected for analysis.  In order to determine if estrogen protected female mice 
from adipocyte oxidative stress, we stained perigonadal adipose tissue with gamma-
H2AX (γH2AX). Images were quantified using Nikon's NIS Elements Software at 20x 
magnification, with six slides taken per group, and two fields per slide. Briefly, the image 
RGB threshold was set in order to account for the stained proteins of the image. After a 
set threshold was applied, the area fraction, object count and total area threshold were 
calculated.  
Quantitative real-time PCR (qRT-PCR) 
 We measured the mRNA levels of CD68, IL6 and TNFα in perigonadal adipose 
tissue to determine if estrogen protected female mice from adipose tissue inflammation. 
Total RNA was extracted from frozen white adipose tissue using an RNAeasy Mini Kit 
(Qiagen, Hilden, Germany) following the manufacturer’s instructions. The amount of 
RNA was determined by measuring the absorbance at 260 and 280 nm. Reverse 
transcription was conducted with a High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA), using 2μg of RNA for each reaction. Real time 
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PCR was performed with a SYBR GreenER qPCR kit (Invitrogen, Carslbad, CA) and a 
Mastercycle Realplex Thermocycler (Eppendorf, Hamburg, Germany). The relative 
expression level of the target genes was normalized to the endogenous reference control 
gene 18s rRNA. Moreover, the male mice were used as the calibrator to which all other 
groups were compared against using the CT method. The primers are available upon 
request.  
Assessment of serum triacylglycerols and free fatty acids 
 To determine if estrogen altered serum lipid levels, we measured serum 
triacylglycerols and free fatty acids.  Mice were fasted three hours prior to necropsy and 
serum was collected.  Serum triacylglycerols were assessed using a triglyceride assay 
from Wako Pure Chemical Industries (Osaka, Japan).  Serum free fatty acids were 
detected using TSZ ELISA free fatty acid kit (Framingham, MA). 
Protein extraction and immunoblotting 
 To gain a better understanding of the role of estrogen in lipolysis, we 
homogenized perigonadal adipose tissue protein lysates in Tissue Protein Extraction 
Reagent (T-PER) (Thermo Scientific, #78510) and prepared the samples according to 
manufacturer’s instructions. Equal amounts of protein (30μg) were subjected to gel 
electrophoresis on a 4-12% Bis Tris gradient gel.  Proteins were then transferred to PVDF 
membranes. The membranes were blocked with 5% non-fat dry milk (NFDM) in tris-
buffered saline with 0.1% Tween (TBST) buffer.  The membranes were immunoblotted 
with antibodies from Cell Signaling (P-HSL (ser563), HSL, PPKA, ATGL, and βActin) 
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at 4°C overnight. Following incubation with the primary antibody, membranes were 
washed in TBST and then exposed to a rabbit secondary antibody conjugated with 
horseradish peroxidase. After secondary antibody incubation, the membranes were 
washed again with TBST followed by enhanced chemiluminescence reagent (ECL) 
(Pierce,Rockford, IL). Bands were quantified using Image J (NIH, Bethesda, MD) as 
previously described [173] 
Liver histology and measurement of serum ALT  
 In order to assess if estrogen modulated liver biology, we collected liver at the 
time of necropsy and fixed it in 10% neutral buffered formalin.  Liver tissue was paraffin-
embedded and cut 5μm thick and then stained with hematoxylin and eosin.  Images were 
taken at a 10x magnification.  To establish if estrogen affected liver inflammation, we 
analyzed levels of serum alanine transaminase (ALT), a biomarker for liver 
inflammation.  Serum was collected from the mice at necropsy and was analyzed using 
an ALT Elisa kit from Bioo Scientific (Austin, TX). 
Insulin tolerance test 
 To determine if estrogen protected female mice from insulin resistance, we 
conducted an insulin tolerance test. Ten randomly selected mice were fasted for 7 hours 
and then intraperitoneally injected with insulin 4.5nmol/g of bodyweight. Blood glucose 
was measured using a Glucometer Elite (Bayer, Elkhart, IN). Approximately half a drop 
of blood was drawn from each mouse tail.  Blood glucose levels were measured at 0, 15, 
30, 60, and 120 minutes from injection time and area under the curve was calculated.  
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Statistics 
 To measure if the effects of both diet and sex were significantly different, results 
were analyzed by ANOVA with pairwise comparisons and a post-hoc comparison of 
means using Tukey’s Honestly Significant Difference.  All results are presented as mean 
± standard error mean (SEM).  SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL, 
USA) was used for all statistical comparisons.  P-values ≤ 0.05 were considered 
statistically significant. 
Results 
Sex differences in bodyweight and adiposity 
 Table 3.1 shows that after 10 weeks of consuming the low-fat diet, male mice 
gained significantly more weight compared to novx-female and ovx-female+E mice 
(p<0.05).  Male mice consuming the high-fat diet gained significantly more body weight 
than novx-female mice (15.3 vs. 7.6g, p < 0.001).  Ovx-female mice mimicked the male 
mice in their bodyweight change (16.5g), but when supplemented with estrogen, their 
change in bodyweight was minimal and similar to the novx-female mice (4.1g, p<0.001).  
This pattern was also seen in total body adiposity levels, which were assessed at baseline, 
5 weeks, and 10 weeks.  After 10 weeks, there was a significant change in adiposity 
levels for mice consuming the high-fat diet.  Briefly, in Table 3.1, male mice increased 
their body adiposity levels by approx 27.7% and ovx-female mice increased their 
adiposity by 36.4%.  However, novx-female mice only increased their adiposity by 
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12.7%, and ovx-female mice supplemented with estrogen only increased their adiposity 
by 3.4%. 
Sex differences in serum triacylglycerols and free fatty acids  
 To assess if sex and estrogen altered lipid metabolism, we measured systemic 
levels of serum triacylglycerols and free fatty acids.  For mice consuming the high-fat 
diet, male mice had significantly higher serum triacylglycerol levels compared to novx-
female and ovx-female+E mice (245±13 vs. 143±13 and 88±5 mg/dL, p<0.05).  In 
addition, ovx-female mice also had higher serum triacylglycerol levels compared to 
novx-female and ovx-female+E mice, but it was only significantly different compared to 
ovx-female+E mice (186±20 vs. 143±13 and 88±5 mg/dL), Table 3.1.  Surprisingly, we 
found that male mice consuming the high-fat diet had significantly lower serum free fatty 
acids compared to novx-female, ovx-female, and ovx-female+E mice (264±26 vs. 
584±38, 680±37, 845±21 nmol/mL, p<0.001), Table 1.  Our data suggest that there are 
possible sex differences in lipid metabolism independent of estrogen.  
Sex differences in adipocyte diameter  
 To determine if sex and estrogen influenced adipocyte morphology, we measured 
adipocyte diameter.  Since the most dramatic changes in body adiposity were observed in 
the mice consuming the high-fat diet, we only measured adipocyte diameter within the 
high-fat diet groups.  Results in Figure 3.1A show that male mice had larger adipocytes 
compared to novx-female mice (75.22±1.16 vs. 59.79±3.23μm, p <0.001).  However, 
adipocyte diameter increased when the ovaries were removed from the female mice 
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(84.88±2.38μm) Figure 3.1B, but decreased when the ovx-female mice were 
supplemented with estrogen (41.48±4.91μm) Figure 3.1C. Our data suggest that estrogen 
decreased the number of large adipocytes in female mice.  
Sex differences in adipose tissue oxidative stress and inflammation  
 In order to determine if there was a relationship between adipocyte hypertrophy 
and adipocyte oxidative stress, we stained perigonadal adipose tissue with gamma-H2AX 
(γH2AX), which has previously been used as a biomarker for oxidative stress [174].  
Figure 3.2A shows images taken at 40x and 63x magnification.  Figure 3.2B shows the 
quantification of γH2AX stained nuclei for images taken at 20x (6 slides per animal and 2 
fields per slide).  Briefly, male and ovx-female mice had significantly more γH2AX 
stained nuclei compared to novx-female and ovx-female+E mice; thus, the data suggest 
that estrogen protects against the development of adipose tissue oxidative stress.  
 To establish if the sex differences we observed in adipocyte oxidative stress were 
also reflected in adipose tissue inflammation, we measured mRNA levels of CD68, IL6, 
and TNFα.  CD68 is a glycoprotein that is used to identify macrophages, IL6 and TNFα 
are pro-inflammatory markers produced by macrophages and adipocytes [175, 176].  
Results show that novx-female and ovx-female+E mice had significantly lower CD68 
and TNFα mRNA levels compared to male and ovx-female mice (-11.8x and -12x vs. 
1.00 and 1.1, p<0.05), Figure 3.3.  Moreover, IL6 mRNA levels were lower in novx-
female and ovx-female+E mice; however, they were not significantly different, Figure 
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3.3. Hence, the data suggest that estrogen protects female mice from adipocyte oxidative 
stress and inflammation.  
Sex differences in lipolysis 
 To determine the sex differences in lipolysis, we assessed protein expression and 
activity in perigonadal adipose tissue in mice consuming the high-fat diet. As shown in 
Figure 3.4A, novx-female and ovx-female+E mice had significantly more phosphorylated 
PKA compared to males. Additionally, novx-female and ovx-female+E mice also had 
significantly more phosphorylated HSL at ser563, which is known to be phosphorylated 
by PKA [177]. Interestingly, ovx-female mice also had an increase in phosphorylation of 
PKA and HSL compared to male mice, although this was not significant, it suggests that 
ovx-female mice may have increased lipolysis. Moreover, the activation of PKA and 
HSL observed in the ovx-female mice may not have been as prominent compared to the 
novx-female and ovx-female+E mice due to the lower ATGL protein expression levels 
detected in the ovx-female mice. Protein expression of ATGL was significantly increased 
in the novx-female and ovx-female+E mice compared to male mice. Figure 3.4B shows 
the quantification of the protein bands; all bands were normalized to β-actin. Our data 
suggests that the presence of estrogen is activating lipolysis in the adipocytes of female 
mice. Furthermore, independent of estrogen, ovx-female mice are also experiencing 
lipolysis, which is contributing to the elevated serum free fatty acids. 
 
Sex differences in liver biology  
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 To gain a better understanding of the role of estrogen and sex in liver biology, we 
collected and hematoxylin- and eosin-stained liver tissue from each group.  Results 
indicate that male mice and ovx-female mice have a higher incidence of steatohepatitis.  
However, steatohepatitis was absent in novx-female and ovx-female+E mice, suggesting 
that estrogen protects female mice from the development of fatty liver (Figure 3.5A).  
Serum ALT is a marker for liver injury; our data show that ovx-female mice had 
significantly higher levels of serum ALT compared to novx-female, ovx-female+E and 
male mice (52.9 vs. 26.8, 23.3, and 33.3 U/L, respectively, p<0.05), Figure 3.5B.   
Sex differences in insulin resistance 
 Both obesity-associated inflammation and steatohepatitis have been strongly 
correlated with insulin resistance; therefore, to determine if there is a relationship 
between steatohepatitis and insulin resistance in regards to sex, we measured insulin 
sensitivity.  Our results demonstrate that estrogen improved insulin sensitivity in female 
mice.  Briefly, when exposed to a high-fat diet, male mice were more insulin resistant 
compared to novx-female mice (Figure 3.6A).  Removal of the ovaries caused the female 
mice to mimic the males’ insulin resistance; however, supplementation with estrogen to 
the ovx-female mice improved their insulin sensitivity to levels similar to novx-female 
mice.  Figure 3.6B is a graphical representation of the calculated area under the curve.  
 
Discussion 
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 Obesity is associated with numerous co-morbidities, such as insulin resistance, 
abdominal adiposity, chronic adipocyte inflammation, insulin resistance, and liver 
steatosis [50].  Insulin resistance and abdominal adiposity are two key criteria that are 
considered when diagnosing an individual with Metabolic Syndrome [178]. Additionally, 
metabolic syndrome is associated with atherosclerosis, altered lipid metabolism, and liver 
steatosis [30]. Our results show that estrogen protects female mice from many of the 
previously mentioned morbidities: insulin resistance, inflammation, and liver steatosis. 
Moreover, our results suggest that estrogen may protect female mice from the above co-
morbidities by modulating adipocyte size.  
 The link between obesity and adipocyte hypertrophy is well established [8].  We 
show that male and ovx-female mice have larger adipocytes than novx-female and ovx-
female+E mice when fed a high-fat diet.  An increase in adipocyte size can potentially 
lead to a hypoxic environment which can worsen an already inflamed milieu and 
augment adipocyte oxidative stress, leading to the production of reactive oxygen species 
(ROS) and the subsequent generation of DNA damage [179]. Oxidative stress is of great 
importance as it has been linked to metabolic syndrome and cancer [180]. Here, we used 
γH2AX, a common biomarker for oxidative stress, to evaluate levels of oxidative stress 
in adipose tissue [174].  Our results show that obese male and ovx-female mice have 
more γH2AX stained nuclei compared to novx-female and ovx-female+E mice.  
Furthermore, it has been established that estrogen can decrease systemic ROS and 
inflammation in endothelial cells and protect against atherosclerosis [82, 83]. In support, 
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our data suggests estrogen protects female mice from adipocyte oxidative stress and may 
aid in preventing adipocyte inflammation. In fact, we show that the adipose tissue of both 
obese ovx-female and male mice contain higher levels of inflammatory markers, Cd68 
and TNFα, compared to novx-female and ovx-female+E mice.  CD68 is a glycoprotein 
highly expressed in tissue macrophages [22] and indicates adipose tissue macrophage 
infiltration.  Results also show that novx-female and ovx-female+E mice are protected 
from insulin resistance when consuming the high-fat diet.  Thus, estrogen may indirectly 
protect against insulin resistance by decreasing adipose tissue inflammation and 
modulating lipid metabolism. Interestingly, we found sex differences in serum free fatty 
acids and triacylglycerols  possibly due to differences in adipocyte lipolysis  Our results 
indicate that male mice had higher serum triacylglycerol levels but lower serum free fatty 
acid levels when consuming the high-fat diet.  However, ovx-female mice fed the high-
fat diet had high levels of both serum triacylglycerols and free fatty acids, implicating sex 
differences in lipogensis and/or lipolysis independent of estrogen.  Even though they 
differ in lipolytic activity, the adipocyte size of male and ovx-female mice is similar.  
Furthermore, others have determined that ovx-female mice and postmenopausal women 
can have large adipocytes despite high lipolytic activity [10,11].  Novx-female and ovx-
female+E mice also had elevated levels of serum free fatty acids, which might be 
explained by the increased activity of key lipolytic enzymes (P-PKA and P-HSL) 
observed in these mice. However, the increase in serum free fatty acids observed in 
female mice may be subjected to different metabolic pathways.  For example, unlike the 
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novx-female and ovx-female+E mice, ovx-female mice had liver steatosis and elevated 
levels of serum ALT, suggesting that the high circulating serum free fatty acids in the 
ovx-female mice were deposited in the liver.  Serum free fatty acids in novx-female and 
ovx-female+E mice might be used for energy through fatty acid oxidation occurring in 
the liver and skeletal muscle.  In fact, studies have shown that estrogen increases the 
expression of genes involved in fatty acid oxidation which suggests that estrogen 
stimulates the use of fatty acids for energy (16).  Therefore, estrogen may aid in 
preventing obesity and its co-morbidities by affecting lipid metabolism.  
 In conclusion, we show that estrogen modulates adiposity by altering adipocyte 
size.  This change in adipocyte biology has beneficial effects on adipocyte inflammation, 
oxidative stress, liver steatosis, and insulin resistance. However, it is still unclear whether 
estrogen protects female mice from adipocyte inflammation and oxidative stress directly 
or indirectly.  Our future studies will aim to clarify this discrepancy and further 
characterize the role of estrogen in these processes.  
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Table 3.1.  Sex differences in bodyweight, adiposity and lipid metabolism.   
a 
Significantly different compared to novx-females and ovx-females+E in the low-fat diet 
group . 
b
 Significantly different compared to novx-females and ovx-females+E in the high-fat diet group, p<0.05.
c
 Significantly different compared to ovx-female+E in 
the high-fat diet group.  
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Figure 3.1: Sex differences in adipocyte diameter. (A) When exposed to a high-
fat diet, male mice had significantly larger adipocytes compared to novx-female 
mice. (B) When the ovaries were removed from female mice, their adipocyte 
diameter mimicked that of male mice.  (C) When estrogen was supplemented to the 
ovx-female mice, their overall adipocyte diameter and size decreased to a size 
similar to that of the novx-female mice 
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Figure 3.2: Sex differences in adipocyte oxidative stress.  Panel A shows perigonadal adipose tissue stained 
for γH2AX.  Images were taken at 40x and 63x magnification; scale bars represent 100μm and 50μm, 
respectively.  Panel B shows the quantification of γH2AX at 20x magnification.  For mice consuming the 
high-fat diet, males and ovx-females had significantly more γH2AX stained nuclei.  Briefly, 6 slides were 
taken per animal and 2 different images were captured per slide.  *Significantly different compared to novx-
female and ovx-female+E, p<0.05 (n=6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
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Figure 3.3: Estrogen decreases inflammation in high-fat fed female mice. RNA 
was isolated from perigonadal adipose tissue from high-fat fed mice and quantified 
using QRTPCR.(A) Cd68 mRNA expression levels. (B) TNFα mRNA expression 
levels. (C) IL6 mRNA expression levels *Significantly different compared to novx-
female and ovx-female+E, p<0.05 (n=6). 
70 
 
 
 
 
 
 
Figure 3.4: Sex differences in lipolysis. (A) Adipose tissue was collected from the 
perigonadal fat pad and 30μg of protein was extracted for western blot analysis. 
Image represents 1 of 3 independent experiments (n=6). (B) All 3 independent 
experiments were quantified using Image J and normalized to β-actin. * 
Significantly different compared to novx-female and ovx-female+E, p<0.05 (n=6). 
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Figure 3.5: Estrogen prevents liver steatosis and decreases serum ALT levels. (A) 
Liver tissue was collected and fixed in 10% neutral buffered formalin and then stained 
with hematoxylin and eosin.  Images were taken at 20x magnification, scale bar equals 
100μm.  (B) Serum was collected 3 hours after fasting and was analyzed for alanine 
transaminase.  Briefly, ovx-females had significantly higher serum ALT levels 
compared to novx-female and ovx-female+E.  *Significantly different compared to all 
groups consuming the high-fat diet, p<0.001 (n=8). 
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Figure 3.6: Estrogen protects female mice from insulin resistance. On the 10th week, ITT was 
performed after a 6hr fast. Mice were injected with 4.5nmol/g of bodyweight of insulin, and a small drop 
of blood was collected from the tail to measure blood glucose levels at 0, 15, 30, 60, 120 minutes after 
injection.  (A)After 10 weeks of consuming a high-fat diet, male and ovx-female mice experience 
significantly more insulin resistance compared to novx-female and ovx-female+E mice. (B)Area under the 
curve was calculated. ** Significantly different compared to novx-female and ovx-female+E consuming 
the high fat diet, p<0.001 (n=10). 
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Chapter 4: The role of estrogen in adipocyte inflammation and oxidative stress: a 
closer look. 
The data presented in this chapter is under review at Diabetes, Obesity and Metabolism.  
Abstract 
Obesity is associated with significant changes in adipocyte biology which can have 
deleterious effects on morbidities, such as adipocyte inflammation and oxidative stress. 
However, there is a lack of understanding of sex differences in regards to the specific 
morbidities mentioned above. Therefore, the objective of this study was to determine the 
role of estrogen in adipocyte inflammation and oxidative stress. To assess the effects of 
estrogen on adipocytes inflammation and oxidative stress, we randomized C57BL/6J 
male, non-ovariectomized female (novx), ovariectomized female (ovx) and 
ovariectomized female mice supplemented with 17β estradiol (ovx-E) to receive a 
calorie-restricted,  low or a high-fat diet (15 mice per group).  We examined perigonadal 
adipose tissue for markers of macrophages and oxidative stress. Using 3t3L1 
preadipocytes, we differentiated the adipocytes in various experimental conditions using 
estrogen and measured markers of adipogenesis, inflammation and oxidative stress. Our 
results show that novx-female and ovx-female+E mice exhibited decreased macrophage 
infiltration as evidenced by decreased F480 staining. Moreover, estrogen inhibited 
adipogenesis in 3t3L1 adipocytes and decreased markers of inflammation. Our 
experiments suggest that estrogen could decrease the above markers of inflammation by 
interacting with estrogen receptor-alpha. Additionally, novx-female and ovx-female+E 
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mice also displayed decreased levels of oxidative stress genes. In 3t3L1 differentiated 
adipocytes exposed to estrogen, ROS production was significantly down regulated. In 
conclusion, estrogen decreases adipocyte inflammation possibly by mediating its effects 
through its estrogen receptor-alpha and protects female mice from oxidative stress by 
possibly decreasing macrophage infiltration. 
Introduction 
 Obesity is formally defined as the existence of excess adipose tissue. [1] 
However, adipose tissue can be deposited in the subcutaneous depots or the intra-
abdominal depots. Accumulation of adipose tissue in the intra-abdominal depots is 
known as visceral adiposity or central adiposity. Central adiposity has been associated 
with many co-morbidities, including but not limited to, low-grade chronic inflammation 
and oxidative stress. [12] Numerous studies have been conducted in order to understand 
the sex differences in adiposity. Briefly, studies have found that males and post-
menopausal females are more likely to store adipose tissue in their intra-abdominal 
depots compared to pre-menopausal females. [11, 19, 23] Moreover, epidemiological 
studies have observed that after adjusting for differences in visceral adiposity, pre-
menopausal females have reduced pro-inflammatory markers compared to males, thus 
suggesting estrogen may have an anti-inflammatory effect. [181] In vitro studies, have 
also found that estrogen has a strong protective effect on neural cells by decreasing pro-
inflammatory markers. [68] Estrogen has also been suggested to protect against oxidative 
stress by decreasing reactive oxygen species (ROS) and inflammation in endothelial cells. 
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[69, 82] However, there is little information discussing the role of estrogen in decreasing 
markers of inflammation and oxidative stress in adipocytes.  
 Previously, our lab has shown that when exposed to a high-fat diet, male and ovx-
female mice gained significantly more weight compared to novx-female and ovx-
female+E mice. [159] The weight gain observed in the male and ovx-female mice was in 
the form of abdominal adipose tissue and was due to an increase in adipocyte size. [128] 
Our lab and others have shown that the small adipocytes observed in the novx-female and 
ovx-female+E mice might be due to an increase in lipolysis.[159, 166, 182] Furthermore, 
the ability of estrogen to reduce the amount of adipose tissue could also be due to its 
effects to hinder adipogenesis. Studies have shown that estrogen could hinder 
adipogenesis by modulating key adipogenic genes. [38] Both a decrease in adipocyte size 
and number could have profound effects on inflammation and oxidative stress. For 
instance, studies have shown that large adipocytes produce excessive amounts of pro-
inflammatory cytokines and ROS and are often surrounded by macrophages, which 
further augment the current stressed milieu. [113, 114, 179] Moreover, in our previous 
work, we observed that estrogen protected the novx-female and ovx-female+E mice from 
adipocyte inflammation and oxidative stress as evidenced by decreased mRNA levels of 
CD68 and TNFα and reduced γH2AX stained nuclei. [159] However, it is unknown if the 
observations we made in our previous studies were due to a direct or indirect effect of 
estrogen to protect the female mice against adipocyte inflammation and oxidative stress. 
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Therefore, the purpose of the current study was to determine if estrogen decreases 
adipocyte inflammation and oxidative stress directly or indirectly by altering adiposity.  
Materials and Methods 
Mouse husbandry and diets  
 A total of 195 pathogen free C57BL/6J male, non-ovariectomized female (novx-
female), ovariectomized female (ovx-female), and sham-ovariectomized female mice 
were purchased from Jackson Labs (Bar Harbor, Maine, USA) at 6 weeks of age and 
housed according to NIH guidelines (National Research Council, 1996) in the Animal 
Resources Center at the University of Texas at Austin.  The animal protocol was 
approved by the Institutional Animal Care and Use Committee at UT-Austin.  The mice 
were singly housed and maintained on a 12hour light–dark cycle and at a temperature of 
22-24°C.  After two weeks of acclimation, the mice were randomized, 15 mice per group, 
to receive one of three semi-purified diet regimens: 1) a 15-30% calorie restricted diet 
(CR; D03020702), 2) a low-fat diet (LF; 10% fat from kcals, D12450B), and 3) a high-fat 
diet (HF; 60% fat from kcals, D12492).  To control for the effects of surgery on 
bodyweight and glucose metabolism, we included sham-ovariectomized female mice who 
consumed the low fat diet (n=15). All diets were obtained from Research Diets, Inc. and 
are semi-purified diets (New Brunswick, NJ, USA).  A table with detailed information on 
these diets was previously described. [141]  The CR diet was modified so that the mice 
received 70-85% (2.7g/day) of the mean daily caloric consumption of their respected 
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control (LF) group, but 100% of the vitamins and minerals. Mice were fed ad libitum or 
calorie-restricted; body weight, food, and liquid consumption were recorded weekly.  
Estrogen supplementation 
To further characterize the role estrogen plays in adipocyte biology and 
inflammation, we implanted a 0.72mg 17β estradiol pellet into ovariectomized female 
mice (ovx-female+E), which delivered 5μg/d.  This dosage protocol is similar to the 
estradiol supplementation used by others and has been shown to re-establish 
physiological estradiol levels in ovariectomized females. [142] Control mice were 
implanted with placebo pellets.  At 9 weeks of age, ovariectomized mice were 
randomized to receive either a placebo or an estradiol pellet.  Mice were anesthetized 
with isoflurane. The dorsal area between the ear and shoulder was shaved and sterilized 
with 70% isopropyl alcohol and a trochar was used to implant the 4.5 mm pellet 
subcutaneously.  
Histology and Immunohistochemistry  
At necropsy, adipose tissue was collected from the intra-abdominal perigonadal 
fat pad, which others have shown to be metabolically significant in regards to adipocyte 
biology and inflammation. [27, 170] Adipose tissue was fixed in 10% neutral buffered 
formalin for 48 hours and then transferred to 70% ethanol indefinitely.  For histological 
analysis, adipose tissue was paraffin-embedded and cut 5μm thick and stained with 
hematoxylin and eosin. All samples were prepared simultaneously and under the same 
protocol.  In order to determine if estrogen protected female mice from macrophage 
78 
 
infiltration when fed a high-fat diet, we stained perigonadal adipose tissue with F480 and 
noted crown-like structures surrounding necrotic adipocytes in mice consuming the high-
fat diet.  Images were taken at 20x magnification.  
Quantitative real-time PCR (qRT-PCR) 
We measured the mRNA levels of genes related to inflammation and oxidative 
stress in perigonadal adipose tissue and 3t3L1 differentiated adipocytes, to determine if 
estrogen altered markers of inflammation and oxidative stress. Total RNA was extracted 
from frozen white adipose tissue using an RNAeasy Mini Kit (Qiagen, Hilden, Germany) 
following the manufacturer’s instructions. The amount of RNA was determined by 
measuring the absorbance at 260 and 280 nm. Reverse transcription was conducted with a 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA), 
using 2μg of RNA for each reaction. Real time PCR was performed with a SYBR 
GreenER qPCR kit (Invitrogen, Carslbad, CA) and a Mastercycle Realplex Thermocycler 
(Eppendorf, Hamburg, Germany). The relative expression level of the target genes was 
normalized to the endogenous reference control gene 18s rRNA. Moreover, the male 
mice were used as the calibrator to which all other groups were compared against using 
the CT method. The primers are available upon request.  
Adipogenesis assay 
To gain a better understanding of the role of estrogen in adipogenesis, 3t3L1 pre-
adipocytes were grown to 100% confluency and induced to undergo adipogenesis two 
days later by culturing the cells in differentiation medium (day 0): DMEM containing 
10% FBS, 0.5 mM isobutylmethylxanthine (IBMX) (Sigma, St Louis, MO), 1 μM 
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dexamethasone (Dex) ((Sigma, St Louis, MO) and 167 μM bovine insulin (Sigma). On 
day 2, after the induction, cells were maintained in post-differentiation medium: DMEM 
containing 10% FBS and 167 μM insulin (I) until Day 8-10 (full differentiation).  
Effects of estrogen on inflammation, oxidative stress and adipogenesis  
To determine whether estrogen affected adipogenesis, adipocytes were 
differentiated in the presence or absence of 1nM estrogen (E) (Sigma, St Louis, MO).  On 
day 10, adipocytes were stained with Oil red O as previously described.[183] Or, 
collected to measure markers of adipogenesis, inflammation and oxidative stress at the 
mRNA level by QRTPCR.   
To assess the effects of estrogen on  markers of adipogenesis and inflammation in 
the presence of excess pro-inflammatory factors, adipocytes were differentiated in 334 
μM bovine insulin (I) and 20 μM arachidonic acid (AA) +/- 1nm E.  We chose to induce 
adipocyte differentiation with AA because it has been shown to promote 
inflammation.[184] Adipocytes were collected on day 10 to measure markers of 
adipogenesis and inflammation by QRTPCR. 
Effects of estrogen on inflammation via ERα 
To establish if the anti-inflammatory effects of estrogen were mediated through 
the estrogen receptor-alpha (ERα), adipocytes were exposed to +/- 1nM E and +/- 100nM 
4-hydroxytamoxifen (Tam) during the differentiation process on day 9. (Sigma, St Louis, 
MO).  Adipocytes were collected to measure markers of inflammation via QRTPCR. 
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Effects of female mouse sera on markers of inflammation and oxidative stress in 
adipocytes 
To determine if the sera from female mice altered pro-inflammatory markers in 
differentiated adipocytes, we exposed the cells to 1% sera from ovx-female mice fed the 
calorie-restricted diet, or novx-female, ovx-female, ovx-female+E mice fed the high-fat 
diet for 24 hours on day 9. Adipocytes were collected on day 10 to measure markers of 
inflammation by QRTPCR. To further characterized the role of estrogen in an obese 
environment, differentiated adipocytes were exposed to 1% obese ovx-female sera +/- 
1nM E for 24 hours on day 9. On day 10, adipocytes were collected to measure markers 
of inflammation by QRTPCR.  
ROS production in adipocytes 
To determine if estrogen modulated ROS production in adipocytes, we exposed 
fully differentiated adipocytes (Day 10) to 0.2% nitroblue tetrazolium (NBT) for 90 
minutes and dissolved in 50% acetic acid and then determine the optical density at 
560nm. The NBT assay was performed as previously described.[179] 
Statistics 
Results were analyzed by ANOVA with pairwise comparisons and a post-hoc 
comparison of means using Tukey’s Honestly Significant Difference or a Student’s t-test.  
All results are presented as mean ± standard error mean (SEM).  SPSS version 16.0 for 
Windows (SPSS Inc., Chicago, IL, USA) was used for all statistical comparisons.  P-
values ≤ 0.05 were considered statistically significant. 
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Results 
Sex differences in adipose tissue macrophage infiltration 
 In order to assess if the enlarged adipocytes we observed in the obese mice from 
our previous studies were associated with macrophage infiltration, we used H&E stained 
perigonadal adipose tissue and determined if crown-like structures (CLS) were present in 
the samples obtained from the mice consuming the high-fat diet. Others have shown that 
the majority of macrophages localized in obese adipose tissue surround dead adipocytes 
forming what is referred as crown-like structures (CLS).[115] Our observations 
confirmed our hypothesis that the necrotic adipocytes observed in the male and ovx-
female mice were surrounded by CLS (Figure 1A); thus, suggesting that the adipose 
tissue in the male and ovx-female mice have a high amount of infiltrating macrophages.  
To confirm macrophage infiltration, we stained the same slides with the macrophage 
marker F480. Results show that the male and ovx-female mice had a high amount of 
infiltrating macrophages, Figure 1B.  Moreover, we show that endogenous (novx-female) 
and exogenous estrogen (ovx-female+E) decreased the amount of infiltrating 
macrophages in the adipose tissue of these mice.  This suggests that estrogen protects 
female mice from adipocyte inflammation partly by decreasing macrophage infiltration.  
Estrogen inhibits adipogenesis but does not inhibit the expression of inflammation 
markers in the presence of excess pro-inflammatory markers. 
 In order to assess the role of estrogen in adipogenesis, we differentiated 3t3L1 
pre-adipocytes in the presence or absence of 1nM estrogen. Our results show that we 
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successfully differentiated 3t3L1 into adipocytes as evidenced by the increased mRNA 
levels of ap2 and leptin, Figure2A. Results also show that estrogen inhibited adipogenesis 
as shown by the significantly lower ap2 mRNA levels, p<0.05, Figure 2A.  Estrogen 
treatment also decreased LPL mRNA levels and Oil R O staining; therefore, suggesting 
that indeed estrogen inhibits adipogenesis in 3t3L1 cells, Figure 2B and C.  
To determine if estrogen inhibits adipogenesis and inflammation in the presence 
of excess pro-inflammatory factors, we differentiated 3t3L1 pre-adipocytes in the 
presence of 20μM arachidonic acid (AA) and 334 μM insulin (I) +/- 1nM estrogen (E). 
We show that excess AA and insulin increased adipogenesis, p<0.05. Moreover, IL6 and 
TNFα were also elevated by the presence of arachidonic acid and excess insulin. Estrogen 
inhibited adipogenesis in the presence of excess AA and insulin, but had no effect on pro-
inflammatory markers, IL6 and TNFα, Figure 2D. 
Estrogen inhibits the expression of inflammation markers via ERα 
 Using 3t3L1 pre-adipocytes, we differentiated the cells in the presence or absence 
of 1nM estrogen. Our results strengthened our previous finding that estrogen decreased 
IL6 and TNFα in the adipose tissue of the novx-female and ovx-female+E mice. We 
demonstrated that 1nM estrogen decreased IL6 and TNFα mRNA expression levels in 
adipocytes, p<0.05, Figure 3A. 
 To determine if the anti-inflammatory effects of estrogen in 3t3L1 adipocytes are 
mediated via the estrogen receptor-alpha (ERα), we differentiated 3t3L1 pre-adipocytes 
in the presence of 1nM estrogen (E) and 100nM 4-hydroxytamoxifen (Tam). Consistent 
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with previous results, we show that estrogen decreased IL6 and TNFα.  However, 
hydroyxtamoxifen (Tam) blocked the effects of estrogen; IL6 and TNFα mRNA levels 
were not decreased by estrogen in the presence of Tam. We measured mRNA levels of 
ERα, which is as an estrogen response gene. As expected, ERα mRNA levels increased in 
the presence of estrogen; however, Tam significantly blocked the expression of ERα by 
estrogen, p<0.05, Figure 3B.  
Sera from obese ovx-female mice increases the expression of IL6 and TNFα and 
estrogen blocks these effects on 3t3L1 adipocytes 
Our previous work suggested that estrogen blocked the pro-inflammatory effects 
of obesity; this notion was supported by the decreased mRNA expression levels of IL6 
and TNFα found in novx-female and ovx-female+E mice consuming the high-fat diet 
(novx-female HF and ovx-female+E HF, respectively)[159]. Similarly, others have 
shown that calorie-restriction (CR) also decreases levels of pro-inflammatory factors 
[185]. However, in the absence of endogenous estrogen, IL6 and TNFα expression 
increased in ovx-female mice consuming the high fat diet (ovx-female HF) [159]. We 
used the sera of ovx-female CR, novx-female HF, ovx-female HF and ovx-female+E HF 
mice to determine if it had similar effects on the expression of IL6 and TNFα in 3t3L1 
adipocytes.  For this purpose, we treated 3t3L1 adipocytes with 1% sera from CR ovx-
female mice and HF novx-female, ovx-female, and ovx-female+E mice. Results show 
that the sera from ovx-female HF mice significantly increased the expression of IL6 and 
TNFα mRNA levels compared to the adipocytes exposed to ovx-female CR mice sera, 
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p<0.05.  However, the expression of IL6 and TNFα was not increased by HF novx-
female and ovx-female+E sera, Figure 4A.  Thus, these results suggest that indeed both 
endogenous and exogenous estrogen have anti-inflammatory properties.  To determine if 
exogenous estrogen was capable of blocking the expression of IL6 and TNFα induced by 
the ovx-female HF sera (obese sera), we treated the adipocytes with ovx-female HF sera, 
as expected the expression of IL6 and TNFα increased; however, the addition of estrogen 
blocked the effects of the obese sera, Figure 4B.  Thus, our findings suggest that estrogen 
blocks the expression of pro-inflammatory factors in adipocytes.   
Estrogen decreases mRNA expression levels of oxidative stress genes and increases 
antioxidant gene expression in female mice 
 To determine if estrogen affected oxidative stress, we measured the mRNA 
expression levels of iNOS, GP91x and P47x in the adipose tissue of the mice consuming 
the high-fat diet. In Figure 5, we show that the male and ovx-female mice had 
significantly higher iNOS mRNA expression levels, p<0.05. Moreover, we measured the 
mRNA expression levels of two of the six subunits of NADPH oxidase. These subunits 
are capable of producing superoxide by transferring electrons from NADPH inside the 
cell across the membrane and coupling these to molecular oxygen. Our result also show 
that novx-female and ovx-female+E mice had significant lower mRNA levels of P47x 
and GP91x p<0.05; thus, suggesting that estrogen possibly protected female mice from 
adipose tissue oxidative stress by decreasing pro-oxidative genes. However, it is possible 
that this effect was partially due to an increase in antioxidant gene expression.  To 
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establish if estrogen could possibly be hindering adipocyte oxidative stress by increasing 
antioxidant gene expression, we measured mRNA expression levels of catalase. In Figure 
5, we show that estrogen significantly increased catalase mRNA expression levels in 
novx-female and ovx-female+E mice consuming the high-fat diet, p<0.05. Therefore, 
estrogen may protect from pro-oxidative stress effects of obesity by decreasing pro-
oxidative stress genes and increasing antioxidant genes.  
Estrogen increases antioxidant gene expression in 3t3L1 adipocytes 
 In order to determine the effects of estrogen on markers of oxidative stress on 
adipocytes, we used 3t3L1 pre-adipocytes. Briefly, the pre-adipocytes were differentiated 
in charcoal-stripped FBS +/- 1nM E and then collected for mRNA analysis on day 10. 
Our findings suggest estrogen may have a more antioxidant role by increasing the mRNA 
expression of catalase rather than inhibiting the mRNA expression of NADPH oxidase 
subunits (P47x and GP91x), although the presence of estrogen did significantly decrease 
GP91x mRNA expression, p<0.05, Figure 6A.  
 To assess the effects of estrogen on pro and anti-oxidant genes in an obese 
environment, 3t3L1 pre-adipocytes were differentiated in charcoal-stripped FBS and then 
were exposed to 1% obese ovx-female sera +/- 1nM E. Our results were similar to the 
previous adipogenesis assays’ findings. The presence of estrogen significantly increased 
the mRNA expression of catalase and decreased the mRNA expression levels of GP91x, 
but the mRNA expression levels of p47x were also increased, Figure 6B.  
Estrogen decreases ROS production in adipocytes. 
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 To gain a better understanding of the role of estrogen in adipocyte oxidative 
stress, we exposed fully differentiated adipocytes to 0.2% NBT. Our results show that 
chronic exposure to 1nM E prevented the formation of adipocytes and also decreased 
ROS production as evidenced by the reduced NBT stained cells, Figure 7 A and B. 
Therefore, implying that the decreased ROS production observed in adipocytes exposed 
to 1nM estrogen could be dependent on the anti-adipogenic effect of estrogen.  
Discussion 
 Obesity is linked with a variety of co-morbidities and many of these morbidities 
are due to changes in the biology of the adipocyte. [12] As obesity progresses excess 
nutrients are stored in adipocytes which eventually leads to adipocyte hypertrophy. [7, 
186] Moreover, obese adipose tissue is characterized by enlarged adipocytes, increased 
macrophage infilitration, increased oxidative stress, and increased pro-inflammatory 
cytokine production. [106, 107, 110-112] Xu et al. and Weisberg et al. both noted the 
increased infiltration of macrophages in expanding adipose tissue as a novel 
physiological event. [113, 114] Due to the increased macrophage infilitration observed in 
obese adipose tissue, many have suggested this plays an important role in remodling the 
obese adipose tissue, since macrophages are well known phagocytes. For instance, 
macrophages have been shown to cluster around necrotic adipocytes forming crown-like 
structures (CLS) in obese adipose tissue. [111, 112, 115, 116] In our study, we observed 
that novx-female and ovx-female+E were protected from macrophage infiltration as 
evidenced by decreased F480 staining. However, these results maybe due to overall 
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smaller adipocytes present in the novx-female and ovx-female+E mice. Therefore, we 
used 3t3L1 pre-adipocytes and differentiated the cells in the presence or absecne of 
estrogen. Briefly, results show that estrogen decreased the expression of both markers of 
adipogenesis and inflammatory (ap2, LPL, IL6 and TNFα). However, in the presence of 
excess insulin and aracahdonic acid, estrogen still hindered adipogenesis but had no 
effect on markers of inflammation. The decreased markers of inflammation in adipocytes 
differentiated in the presence of estrogen could be due to the fewer adipocytes present, 
since others have shown that 3t3L1 adipocytes can express markers of inflammation and 
oxidative stress [179]. Therefore, to address this concern and to determine if exogenous 
estrogen was capable of inhibiting the expression of these pro-inflammatory markers in 
an obese environment, we exposed already differntiated adipocytes to 1% obese ovx-
female sera +/- 1nM estrogen. Our data demonstrated that estrogen was still able to 
decrease both IL6 and TNFα in an obese millieu. Our results suggest that estrogen 
mediates its anti-inflammatory effects via ERα. In support of this notion, in vitro studies 
have established a role for estrogen in decreasing pro-inflammatory cytokines via the 
ERα pathway in neural cells.[72, 73] Also, the anti-inflammatory properties of estrogen 
can be partially explained by the ability of ERα to hinder the activity of nuclear factor 
kappa B (NFĸB) through protein to protein interactions and to act as a transcriptional 
repressor. [69, 75, 76]  
 Enlarged adipocytes can become necrotic or apoptotic for numerous reasons; 
however, a particular cause is oxidative stress due to hypoxia and endoplasmic reticulum 
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(ER) stress. As adipose tissue expands it creates areas of hypoxia and the adipose tissue 
becomes poorly oxygenated and thus induces several pro-inflammatory pathways and 
promotes necrosis of the adipocyte. [118-120] Moreover,  as excess nutrients continue to 
expand the enlarged adipocye, the ER reaches a stress threshold that activates the unfoled 
protein response (UPR). UPR is a signal for apoptosis and further augments the alreadly 
inflammaed milieu of the obese adipose tissue and can lead to DNA damage. In our 
previous studies, we observed that novx-female and ovx-female+E mice displayed fewer 
γH2AX stained nuclei compared to male and ovx-female mice [159]. To elaborate on this 
finding, we examined mRNA levels of key oxidative stress and antioxidant genes. 
Briefly, we observed that the novx-female and ovx-female+E mice fed the high-fat diet 
had lower mRNA levels NADPH oxidase subunits (gp91x and p47x) and iNOS but 
higher levels of catalase. Others have shown that estrogen can decrease ROS production 
in endothelial cells by reducing the expression of NADPH oxidase subunits [82, 83]. To 
further characterize the role of estrogen in adipocyte oxidative stress, we measured 
mRNA levels of adipocytes exposed to estrogen and discovered that estrogen 
significantly down regulated gp91x and increased catalase mRNA levels. Furthermore, 
we stained adipocytes differentiated in the presence or absence of estrogen with 0.2% 
NBT and observed that the adipocytes differentiated with estrogen had decreased ROS 
production. However, this observation may be due to the reduced number of adipocytes, 
since we also observed estrogen hinders adipogenesis and others have shown that this 
stain primarily targets mature adipocytes. [179] Therefore, we repeated our adipogenic 
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assays but waited til day 9 to expose the adipocytes to obese sera +/- 1nM estrogen. 
Briefly, our results showed unclear data regarding a direct role for estrogen in mediating 
its protective effects against oxidative stress. However, we believe that estrogen is 
protecting female mice from oxidative stress indirectly by possibly hindering macrophage 
infiltration which could be dependent on adipocyte size. Our previous studies have shown 
that estrogen protects female mice from adipocyte hypertrophy and our current study 
shows that the female mice had decreased levels of macrophage infiltration.[128, 159]  
 In conclusion, our results show that estrogen protect female mice from 
macrophage infiltration, which could play a significant role in protecting the female mice 
from oxidative stress. Furthermore, our data suggests estrogen could decrease adipocyte 
pro-inflammatory markers by directly interacting with ERα. Future studies should be 
conducted to further elucidate the mechanism by which estrogen interacts with ERα to 
decrease adipocyte inflammation.  
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Figure 4.1:  Estrogen inhibits crown-like structure formation and 
macrophage infiltration.  (A) Adipose tissue was collected from the 
perigonadal region from all groups consuming the high-fat diet and 
stained with hematoxylin and eosin. Images were captured at 20x 
magnification. (B) In order to confirm macrophage infiltration, adipose 
tissue was stained F480.  Images were taken at 20x magnification.  
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Figure 4.2:  Estrogen inhibits adipogenesis but does not inhibit the expression of 
inflammation markers in the presence of excess pro-inflammatory markers. (A) RNA 
was isolated on Day 10 from fibroblasts and adipocytes differentiated in charcoal-stripped 
FBS +/1 nM estrogen (E) and quantified with ORTPCR. * Significantly different compared 
to fibroblasts <0.05 (n=9). (B, C) On day 10, adipocytes +/- 1nM E were collected for 
QRTPCR analysis or stained with Oil Red O. * Significantly different compared to 
adipocytes, p<0.05 (n=9). (D) Adipocytes differentiated in charcoal-stripped FBS +/- 
20μM arachidonic acid (AA) and 330μM insulin (I) +/- 1nM estrogen (E) and quantified 
using QRTPCR. * Significantly different compared to adipocytes, p<0.05 (n=9). ** 
Significantly different compared to all other groups, p<0.05 (n=9) 
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Figure 4.3: Estrogen inhibits pro-inflammatory markers in 3t3L1 differentiated 
adipocytes via ERα. RNA was isolated on day 10 and quantified using QRTPCR for the 
following four experiments. (A) Pre-adipocytes were differentiated in charcoal-stripped 
FBS +/- 1nM estrogen (E). *Significantly different compared to adipocytes, p<0.05 (n=9). 
(B) Adipocytes were differentiated in charcoal stripped FBS +/- 1nM E and +/- 100nM 4-
hydroxytamoxifen (Tam) and collected on day 10. * Significantly different compared to 
adipocytes and adipocytes+1nM E and 100nM Tam, p<0.05, (n=8). ** Significantly 
different compared to adipocytes+1nM E, p<0.05 (n=8). 
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Figure 4.4: Estrogen decreases pro-inflammatory markers in adipocytes exposed to 
high-fat female mice sera. (A) Adipocytes were exposed to 1% CR ovx-female mice or 
HF novx-female, ovx-female, and ovx-female+E mice on day 10. *Significantly different 
compared to adipocytes exposed to CR ovx-female mice sera, p<0.05 (n=9) (B) Adipocytes 
were exposed to 1% obese ovx-female mice sera +/- 1nM E on day 10. *Significantly 
different compared to adipocytes exposed to obese ovx-female mice sera, p<0.05 (n=9). 
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Figure 4.5: Estrogen decreases mRNA expression levels of oxidative stress genes and 
increases antioxidant gene expression in female mice. RNA was isolated from 
perigonadal adipose tissue and quantified using QRTPCR. *Significantly different 
compared to novx-female and ovx-female+E, p<0.05 (n=6). 
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Figure 4.6: Estrogen increases antioxidant gene expression in 3t3L1 adipocytes. (A) 
RNA was isolated on Day 10 from pre-adipocytes differentiated in charcoal-stripped FBS 
+/- 1nM estrogen (E) and quantified using QRTPCR *Significantly different compared to 
adipocytes, p<0.05 (n=9). (B) RNA was isolated on Day 10 from pre-adipocytes 
differentiated in charcoal-stripped FBS and then exposed to 1% obese ovx-female mice 
sera +/- 1nM E and quantified using QRTPCR *Significantly different compared to 
adipocytes exposed to obese ovx-female mice sera, p<0.05 (n=9). 
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Figure 4.7: Estrogen hinders ROS production in 3t3L1 adipocytes. On Day 10, 
adipocytes were treated with 0.2% NBT for 90 minutes and dissolved in 50% acetic acid 
and then collected to determine the optical density at 560nm. (A) Images were captured on 
day 10. (B) Adipocytes were collected and quantified as described above. *Significantly 
different compared to adipocytes, p<0.05 (n=9). 
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Chapter 5: Summary and Future Directions 
Summary 
Obesity is formally defined as the accumulation of excess adipose tissue. 
Excessive adipose tissue in the abdominal region contributes to the deleterious effects of 
obesity. Increased abdominal adiposity is associated with low-grade inflammation, 
oxidative stress and insulin resistance; moreover, there are sex differences in the above 
morbidities. In this dissertation, we hypothesized that estrogen regulates obesity 
associated inflammation, oxidative stress, and insulin resistance through modulation of 
adiposity.  
In the second chapter, we assessed the effects of estrogen on abdominal adiposity 
and glucose tolerance in female mice. When fed a high-fat diet, male and ovx-female 
mice had a greater susceptibility to obesity than novx-female and ovx-female mice. Male 
and ovx-female mice gained weight predominately in the form of abdominal adipose 
tissue due to an increase in adipocyte size. Moreover, male and ovx-female mice had 
significantly higher mRNA levels of leptin and lower mRNA levels hormone-sensitive 
lipase relative to novx-female and ovx-female+E mice. Additionally, estrogen had a 
strong inhibitory effect on key adipogenic genes in novx-female and ovx-female+E mice. 
Lastly, we showed that male and ovx-female mice had a higher incidence of glucose 
intolerance. In conclusion, estrogen protected female mice from obesity and impaired 
glucose tolerance possibly by modulating the expression of genes regulating 
adipogenesis, lipogenesis, and lipolysis [128]. 
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 In the third chapter, we determined that estrogen decreased adipocyte size and 
protected female mice from markers of adipose tissue inflammation and oxidative stress, 
and insulin resistance. Our results demonstrated that male and ovx-female mice 
consuming the high-fat diet had a higher propensity of gaining weight, specifically in the 
form of body fat.  However, estrogen protected female mice from adipocyte hypertrophy 
and from developing adipose tissue oxidative stress and inflammation. Moreover, novx-
female and ovx-female+E mice had more phosphorylated levels of PKA and HSL, 
markers associated with lipolysis. Additionally, male and ovx female mice had a higher 
propensity of developing liver steatosis and insulin resistance.  In summary, we showed 
that estrogen protects female mice from adipocyte hypertrophy and adipose tissue 
oxidative stress and inflammation.  Furthermore, estrogen prevented female mice from 
developing liver steatosis and from becoming insulin resistant [159]. 
 In the fourth chapter, we further investigated the anti-inflammatory and anti-
oxidant effects of estrogen in adipose tissue and in 3t3L1 adipocytes. Our results 
displayed that novx-female and ovx-female+E mice exhibited decreased macrophage 
infiltration as evidenced by decreased F480 staining. Moreover, estrogen inhibited 
adipogenesis in 3t3L1 adipocytes and decreased markers of inflammation. Our 
experiments suggest that estrogen could lower the above markers of inflammation by 
interacting with estrogen receptor-alpha. Additionally, novx-female and ovx-female+E 
mice also displayed decreased levels of oxidative stress genes in adipose tissue; 
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furthermore, in 3t3L1 differentiated adipocytes exposed to estrogen, ROS production was 
significantly down regulated. In conclusion, estrogen may hinder adipocyte inflammation 
by mediating its effects through estrogen receptor-alpha and protect female mice from 
oxidative stress by possibly decreasing macrophage infiltration. 
 In summary, this thesis has provided evidence that suggests estrogen protects 
female mice from obesity and its co-morbidities by preventing the accumulation of 
abdominal adiposity. Specifically, estrogen hindered lipogenic and adipogenic gene 
expression and increased lipolysis as evidenced by activation of PKA and HSL. 
Moreover, our data suggests a strong anti-inflammatory role for estrogen in adipose 
tissue as demonstrated by the decreased macrophage infiltration and mRNA expression 
of pro-inflammatory markers. Additionally, we provided preliminary evidence that 
suggests estrogen my minimize pro-inflammatory markers by interacting with ERα in 
3t3L1 differentiated adipocytes. However, the role of estrogen in oxidative stress is most 
likely an indirect role and is possibly dependent on macropahge recruitment and 
adipocyte size. Due to the beneficial effects of estrogen on adipose tissue inflammation 
and oxidative stress, it can also protect against insulin resistance. We demonstrated that 
estrogen protected female mice from makers of insulin resistance by performing GTT, 
ITT and examing liver pathology. The major findings from this thesis our summarized in 
Figure 5.1.  
 Although this dissertation provides strong evidence suggesting that estrogen 
modulates adipocyte morphology and protects female mice from obesity-associated 
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inflammation, oxidative stress and insulin resistance, it contain few weaknesses. First, all 
of our experiments were conducted in a diet-induced obesity mouse model; therefore, it is 
difficult to translate our findings to a human population. For example, in order to mimic 
the menopause transition in our mice, we removed the ovaries, which are responsible for 
producing both estrogen and progesterone [187]. Moreover, the ovx-female+E mice 
group, was only supplmented with estrogen and not progesterone; thus, both the ovx-
female and ovx-female+E have limited translatablity and can not be fully compared to 
post-menopausal females or post-menopausal females receiving HRT. Second,  the high-
fat diet food we fed the mice is not representative of the typical American diet. The high-
fat diet is mocomposed of 60% fat in mostly the form of lard; however, the typical 
Western diet is composed of saturated, trans, and unsaturated fatty acids [188]. Moreover, 
the high-fat diet fed to our mice was low in carbohydrates and the Western diet is high in 
carbohydrates, specifically high-fructose corn syrup [188]. Third, for our in vitro studies, 
we used 3t3L1 mouse pre-adipocytes. Again, this limits the translability of our results to 
a human population. This caveat could be eliminate by carrying out the in vitro studies 
using human pre-adipocytes, moreover, the results obtained from such studies would be 
more directly related to human biology. Finally, we have shown the beneficial effects of 
estrogen, but it is important to highlight that estrogen can also have deleterious effects. It 
has been established that estrogen can  increase breast cancer risk in post-menopausal 
women [189]. High levels of estrogen enhance the risk of breast cancer in post-
menopausal females by stimulating tumor initiation, growth, and progression [190]. 
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Moreover, estrogen can also augment the risk of severe cardiovasuclar events such as 
strokes, heart attacks, and thrombosis in post-menopausal females [189].   
The data presented in this dissertation are limited to mouse animal and cell 
models. However, the potential mechanisms identified in our data such as the anti-
inflammatory role of estrogen in adipocytes could be targeted by select and specific 
pharmaceuticals in order to address the public health issue of obesity and it co-
morbidities.  
Future Directions 
 These studies provide insight into how estrogen modulates the co-morbidities of 
obesity by targeting adipocyte biology. Specifically, we demonstrated that estrogen 
decreased pro-inflammatory markers (IL6 and TNFα) in 3t3L1 adipocytes, Figure 4.3A. 
Furthermore, using 4-hydroxytamoxifen, we observed that the anti-inflammatory effects 
of estrogen on 3t3L1 adipocytes were blocked, Figure 4.3B. Therefore, suggesting that 
estrogen might mediate its anti-inflammatory effects through the ERα. As discussed 
extensively, adipocyte inflammation has both localized and systemic effects. Particularly, 
pro-inflammatory markers can further augment adipocyte inflammation by recruiting 
macrophages and promoting oxidative stress [106, 126]. Also, the inflamed adipocyte 
milieu can contribute to insulin resistance [117]. Therefore, understanding how the 
interaction between estrogen and ERα decreases pro-inflammatory markers in 3t3L1 
adipocytes should be further clarified. 
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(i) To validate that the anti-inflammatory effects of estrogen are mediated through 
ERα:  Since tamoxifen can interact with multiple estrogen receptors [191], it is important 
to confirm that the phenomenon we observed in our experiment (Figure 4.3B) are 
mediated via ERα. To determine if estrogen decreases pro-inflammatory markers via ERα 
in mature adipocytes, a possible approach will be to silence the ERα gene in mature 
adipocyte and then measure the mRNA expression levels of pro-inflammatory markers as 
a response to estrogen exposure.   If the mRNA levels of the pro-inflammatory markers 
are increased or not changed after silencing ERα, then it will strongly suggest that the 
anti-inflammatory effects of estrogen in adipocytes are mediated via ERα.  
(ii) To determine if estrogen-activated ERα decreases pro-inflammatory markers by 
interacting with NFĸB:  Studies show in neural and immune cells that the activation of 
ERα by estrogen is able to reduce the levels of nuclear DNA-binding activity of NFĸB 
[69, 75, 76]. However, it is not clear if the inhibition of DNA-binding activity of NFĸB 
by ERα is mediated via (A) a direct interaction between ERα and NFĸB or (B) if ERα 
inhibits NFĸB indirectly by modulating IĸB. (A) Thus, to determine if ERα directly 
inhibits NFĸB in mature adipocytes, we can assess the ability of ERα to prevent NFĸB 
from binding to the DNA by using an electrophorectic mobility shift assay (EMSA). 
Additionally, the Luciferase Assay System can be use to determine if estrogen-activated 
ERα alters the ability of NFĸB to bind to the promoter region and induce the expression 
of pro-inflammatory genes.  On the other hand, estrogen activated ERα may inhibit NFĸB 
transcription activity by interacting with its coactivators; therefore, to test this interaction 
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in adipocytes, we may measure the binding of NFĸB to its co-activators, such as Bcl-3.  
This may be done by immunoprecipitating NFĸB, and then determining the factors bound 
to NFĸB such as Bcl-3 or even ERα, by the technique of western blotting.  (B) To 
determine if ERα hinders NFĸB transcriptional activity by an indirectly mechanism, we 
could measure factors that are known to inhibit NFĸB, such as IĸB. Briefly, in the NFĸB 
canonical pathway, extracellular signals can stimulate the IKK complex, which stimulates 
phosphorylation of IĸB and ultimately degradation via a ubiquitination dependent 
mechanism.  Thus, it is possible that ERα may alter IĸB levels by (1) preventing IKK 
from phosphorylating IĸB or (2) preventing the degradation of IĸB by ubiquitination. (1) 
To measure the effects of ERα on IKK phosphorylation, we could measure the cystolic 
total IKK protein and cystolic phosphorylated IKK protein. To assess the relationship 
between ERα and the ubiquitination of IĸB, we could use the ubiquitination assay.  The 
ubiquitination assay measures the amount of ubiquitinated IĸB. The above future 
directions would provide a potential mechanism by which estrogen decreases the 
expression of pro-inflammatory markers in adipocytes by hindering NFĸB transcription 
activity through ERα. This hypothesized mechanism is summarized in Figure 5.2.  
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Figure 5.1 Summary of Major Findings. (A) Our results and others have shown that 
estrogen (E) can affect adipocyte number by altering essential adipogenic genes. (B) Our 
studies have observed that estrogen decreases adipocyte size by activating necessary 
lipases. This protection against adipocyte hypertrophy can decrease macrophage infiltration 
and oxidative stress, which hinders adipocyte inflammation. (C) We have preliminary 
evidence suggesting estrogen could decrease adipocyte inflammation by interacting with its 
estrogen receptor-alpha (ERα). Both (B) and (C) pathways can contribute to the protective 
effects of estrogen against markers of insulin resistance.  
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Figure 5.2 Summary of Future Directions. Shown is the canonical NFĸB pathway where 
an extracellular stimulus activates the IKK complex. IKK phosphorylates IĸB and targets it 
for degradation by ubiquitination; this releases the NFĸB complex and leads to the nuclear 
accumulation of NFĸB and the up-regulation of its target genes. (*) Using SiRNA we 
would validate that estrogen interacts with ERα to decrease pro-inflammatory markers. 
(A1) Estrogen-activated ERα could directly affect the ability for the NFĸB subunits to bind 
to DNA. (A2) Estrogen-activated ERα could directly interfere with NFĸB’s transcriptional 
activity by hindering its co-activators. (B1) Estrogen-activated ERα could indirectly inhibit 
NFĸB by preventing the phosphorylation of IĸB. (B2) Estrogen-activated ERα could hinder 
NFĸB by altering the ubiquitination of IĸB. 
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